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-I njectable Progestogens
Officials Debate
But Use Increases
The place of the injectable progestogen in family planning
remains uncertain. Although some compounds have been
used as injectable contraceptives for over a decade and are
both popular and effective, controversy still surrounds
them ,

Depo-Provera ® (depot medroxyprogesterone acetate), a
product of the Upjohn Company, USA, is currently the only
injectable progestogen in widespread use; it is available
commercially for contraceptive purposes in 64 countries,
Another will be available soon , Schering AG of the Federal
Republic of Germany is now registering an injectable
progestogen, norethindrone enanthate (also known as
norethisterone enanthate) in some 70 countries , It will be
marketed commercially under the brand name Norigest ®
and available for family planning organizations under the
brand name Noristerat ®,

Injectable progestogens offer many advantages that may
be of special importance in developing countries, They are:
• highly effective in preventing pregnancy, on a par
with oral contraceptives ,
• independent of coitus ,
• simple to administer,
• long-lasting, with injections required only two or
four times a year,
• not lactation suppressors and thus, unlike combina
tion oral contraceptives, can be offered to nursing
mothers without danger of reducing the supply of
milk,
• popular in developing countries where injections are
associated with safe, effective, modern medicine,

An estimated 1 million women now depend on injectable
progestogens for contraception , That number is small com
pared with the 50 million who use oral contraceptives and
the 15 million who use intrauterine devices (IUDs), but the
use of injectables appears to be gradually increasing. In
recent years international donors of contraceptive supplies
have received a growing number of requests for injectables
and several countries have added Depo-Provera to their
national family planning programs,
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The injectable progestogens are not without problems.
Over the short run, they disturb menstrual patterns in
many women and cannot be immediately withdrawn if
other problems arise . Over the long run, the return of
fertility after discontinuation may be delayed, especially
with Depo-Provera,
Because of suspicions about other long -term effects, the
use of Depo-Provera has been limited, In some countries
concern about permanent infertility after injections has
caused it to be restricted to older women with completed
families , In other countries Depo-Provera has not yet won
regulatory approval for general use. A controversy in the
USA over the interpretation of statistical data on cervical
carcinoma in situ has prevented approval specifically for
contraception. The US Food and Drug Administration
(USFDA) is reanalyzing the raw data on cervical carcinoma
in situ, a possible precursor of invasive cancer. A report is
expected in 1975,
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An injectable contraceptive is a welcome addition to family
planning methods. But the present progestogen injec
tables, troubled as they are by menstrual side effects and
unresolved questions about long-term effects, have not yet
won the unqualified approval of clinicians . Nevertheless, if
further research can dispel fears about carcinogenicity and
disprove or define the risk of infertility after Depo-Provera
use, the injectable progestogens may yet become an
important component of family planning programs, espe
cially in areas where treatment by injection is popular.

HISTORY
The first systemic contraceptives, developed in the mid
1950s, were Short-acting progestogens administered orally
(128). With the development of longer-acting proges
togens shortly thereafter, injectable contraceptives also
became possible. Over the past 20 years a number of
compounds have been tested as injectable contraceptives,
but only one-Depo'-Provera-is currently being produced
for international distribution and is widely used. In the
USA, Depo-Provera has a checkered history of regulation
and at present is not approved for contraception .
The development of progestogens (synthetic compounds
with the effects of the natural hormone progesterone)
grew out of the post-World War II competition among drug
companies to create synthetic hormones for a variety of
therapeutic purposes. These early progestogens are me
tabolized quickly and therefore have to be administered in
frequent small doses in order to maintain their effect. As a
result, when in the early 1950s Dr. Gregory Pincus and his
associates set about utilizing the powerful ovulation
inhibiting properties of these progestogens for fertility
control, they concentrated on developing a contraceptive
which could be administered orally .
Dr. Karl Junkmann in 1953 discovered that esterifying a
progestogen alcohol created a drug with long lasting
effects when injected (20, 62). (Esters are formed from a
free alcohol and an acid by the removal of water.) Junk
mann and his associates synthesized esters of the proges
togen norethindrone, including norethindrone enanthate,
in 1958 (63) . Medroxyprogesterone acetate was developed
by the Upjohn Company at about the same time (6).
Schering AG began clinical studies of norethindrone enan
thate (Norigest) in 1957. The major field trials of this drug
were conducted in Peru, but other studies have taken
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place in Egypt, Europe, and elsewhere. In 1967 Norigest
was first marketed in Peru, but in 1971 it was withdrawn
and field trials suspended pending further analysis of
toxicologic findings in rats. Some researchers have since
concluded that the findings in rats are not applicable to
humans, and Schering AG is now registering Norigest in
some 70 countries . The brand name Noristerat will be
used when the drug is sold to international donor organi
zations in order to make it readily identifiable if it should be
d iverted from intended channels (25).
In 1958 the Upjohn Company began clinical trials of
medroxyprogesterone acetate (Depo-Provera) as a treat
ment for threatened or habitual abortion and for endome
triosis. In 1960, the USFDA approved it for these uses on
the basis of its safety, but without assessing its effective
ness. In February 1974, after the agency concluded that
Depo-Provera had not been proved effective for either of
these uses and after steroids administered during preg 
nancy had been associated with congenital defects (69,
117). the USFDA withdrew its approval for use of Depo
Provera during pregnancy or to treat endometriosis (33,
34, 35).
The first clinical trials of Depo-Provera as a human contra
ceptive began in 1963 and established a standard regimen
of 150 mg every three months. Field trials began in 1965
and have since been conducted in 61 countries (48). Since
the late 1960s regimens of 300 or 400 mg every six
months have also been studied.
Upjohn applied to the USFDA in 1967 for permission to
market Depo-Provera as a contraceptive in the USA (173),
but, at first, questions about reversibility and relationship
to breast cancer in beagle dogs and, more recently, ques
tions about cervical carcinoma in situ in humans have
blocked USFDA approval.
In 1972 Depo-Provera received USFDA approval as a
palliative treatment of advanced endometrial cancer. Cur
rently this is the only approved use in the USA (168). Depo
Provera has also been studied as a treatment for idiopathic
precocious puberty (64, 83, 106), but its effectiveness and
safety for this purpose have not been established .
Several combinations of a progestogen and an estrogen
are being distributed in a few countries as monthly injec
tables . Promeco markets the combination of algestone
acetophenide and estradiol enanthate in Mexico and Argen
tina under the brand name Perlutal® and in Spain under
the brand name Topasel ®. In Chile, Recalcine Labora
tories produces Aguria ®, and Silesia Laboratories
produces Unalmes®. Both are combinations of dihy
droxyprogesterone acetophenide and estradiol enanthate.
Other steroids have also been tested as injectable contra
ceptives, but are not being pursued because of the ex
pense of clinical trials needed to prove safety (130) and / or
the severe disturbances of the menstrual cycle which they
produced (67, 74, 109). These other injectables include
Deladroxate ®, developed by E. R. Squibb & Sons, USA,
which was a combination of dihydroxyprogesterone aceto
phenone and estradiol enanthate, for monthly injection;
chlormadinone acetate, manufactured by E. Merck
Darmstadt. FRG; and hydroxyprogesterone caproate, man
ufactured by Schering as Prolutin Depot® and marketed by
Squibb as Delalutin®. A few trials have also been con

gesterone acetate, on the other hand, is structurally simi 
lar to progesterone.
Progestogens probably affect ovulation by acting on the
hypothalamus-pituitary axis, causing suppression of the
surge of luteinizing hormone (LH) normally seen at mid
cycle just prior to ovulation (38, 42, 74, 108, 112, 131,
139, 161). Without that surge ovulation does not take place.

Fig. 1 . A woman receives an injection of Depo-Provera
from a nurse at the McCormick Hospital Family Planning
Clinic, Chiang Mai, Thailand . (Courtesy of Dr. E. B.
McDaniel.)

ducted combining Depo-Provera with estradiol cypionate
(17, 78, 153), Norigest with estradiol undecylate (66).
norgestrel with estradiol benzoate (21), and utilizing the
estrogen estradiol undecylate alone (28, 67).
Recent interest in progestogen-only contraceptives repre
sents a return to the intentions of early researchers in
steroidal contraception . They originally envisioned oral
contraceptives as pure progestogens but then discovered
that small amounts of estrogen, present as contaminants,
reduced the breakthrough bleeding caused by the proges
togens. As a result, manufacturers added controlled
amounts of different estrogens to the pills (77). Estrogen,
however, may cause annoying side effects such as nausea,
dizziness, and breast tenderness (22) as well as other,
more serious conditions (55) . To avoid estrogens, investi
gators in the late 1960s turned their attention back to
progestogen-only formulations-in the form of either oral
"minipills" or injectables.

The injectable progestogens make cervical mucus scant,
viscous, and sticky, as it is during pregnancy and during
the infertile late portion of the menstrual cycle (4, 29, 112,
131, 184). This mucus interferes with the movement of
sperm into the uterus. Post-coital tests have shown that
some sperm penetrate the viscous cervical mucus but
rarely reach the uterine cavity or the oviducts (29, 70, 71,
181, 188). With Norigest changes in cervical mucus ap
pear during the first month after the first injection (29) .
With Depo-Provera, changes appear during the second
month (30).
Under progestogen contraception, the endometri um be
comes unable to support a fertilized ovum . With Depo
Provera, the endometrium takes on a resting or atrophic
appearance which becomes more apparent as use contin
ues (30, 112). With Norigest the effects vary. In some
cases the endometrium resumes normal cyclic changes
during the second month after an injection (20, 74) . In
other cases it may remain unsuitable for implantation
throughout Norigest use (4, 29). Both injectables also
appear to cause changes in the oviducts, interfering with
ovum transport and / or sperm capacitation and transport
(12, 30, 184).

EFFECTIVENESS

The standard regimens of Depo-Provera and Norigest offer
highly effective protection against pregnancy. Among

MECHANISM OF ACTION
The injectable progestogens prevent pregnancy in much
the same way that combined oral contraceptives do, and
with the same high degree of effectiveness, by
• inhibiting ovulation in many women
• increasing the viscosity of cervical mucus, thus
forming a barrier to spermatozoa
• changing the rate of ovum transport through the
oviducts
• making the. endometrium less suitable for implanta
tion.
The contraceptive effect of Depo-Provera depends primar
ily on its ability to stop ovulation. Norigest works largely by
altering cervical mucus (72, 74). After the first six to eight
weeks, women using Norigest often do ovulate (4, 7, 73).
The two injectables differ slightly in their effects, possibly
because they are derived from different sources. Norethin
drone enanthate, like most progestogens currently used in
oral contraceptives, is derived from 19-nortestosterone,
which is structurally similar to testosterone . Medroxypro

Fig. 2. Advertisements for Depo-Provera in several
languages reflect widespread use of the injectable .
(Courtesy of the Upjohn Company .)
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women receiving injections of 150 mg Depo-Provera at
90-day intervals or 200 mg Norigest at 84-day (12-week)
intervals, fewer than one in a hundred women are likely to
become pregnant during a one-year period (see Tables 1
and 2). The injectables are as effective in preventing
pregnancy as combined estrogen-progestogen pills,
slightly more effective than progestogen-only "minipills,"
and markedly more effective than IUDs.

reported for women uSing Norigest appear to be slightly
higher (see Table 1). With both drugs, most accidental
pregnancies occur either shortly after the first injection,
before the drug has fully taken effect, or just before the
end of an injection interval when its effect has begun to
wear off (74, 78, 81, 136). Some failures have also been
attributed to injections which were not administered deep
in the deltoid or gluteal muscle as required (186).

Data on the effectiveness of the 150 mg/3 month regimen
of Depo-Provera shown in Table 1 represent over 20,000
woman-years of experience with the drug . Less extensive
studies using 300 or 400 mg Depo-Provera at six-month
intervals have also been conducted (see Tables 1 and 2).

SHORT-TERM SIDE EFFECTS

There are not as many published studies of Norigest as of
Depo-Provera (150 mg/ 3 months). but the pregnancy rates

Though highly effective and easy to administer, the inject
able progestogens are not without problems. In the short

Table 1-Effectiveness of Injectable Progestogen Contraceptives in Selected Studies, 1967-1975
Author & Date of Publication

Reference
Number

Area

Number of
Patients

Number of
Woman-Months

Number of
Pregnancies

Method
Failure Rate a

Depo-Provera (150 mg/3 months)
Apelo et al. 1974
Bloch 1971

3

Philippines

9

South Africa

226

5,109

0

7,335

38,714

11

0
.35

Brat 1971

11

Belgium

584

4,677

3

.77

Chinnatamby 1971

16

Sri Lanka

1,000

18,261

3

.02

Dodds 1971

23

Hong Kong

1,883

30,734

.04

EI-Mahgoub etal. 1972

27

Egypt

231

4,671

0

Koetsawang et al. 1974

81

Thailand

886

24,399

25

0

Leiman 1972

87

South Africa

1,507

12,819

1

.09

Linthorst et al. 1972

88

Netherlands

690

5,009

3

.n

0

1.2

Mishell et al. 1971 b

111

USA

312

5,377

Nunez 1970

122

Honduras

250

2,490

.48

Powel! & Seymour 1971

129

USA

1,123

14,001

.09

Schwallie & Assenzo 1973

150

USA & Latin America

3,857

72,215

0

.25

15

.23

Scutchfield et al. 1971

154

USA

650

4,958 .5

Soichet 1969 b
Tyler 1970b

157

USA

298

4,128

166

USA

214

2,514

0

Zanartu & Onetto 1972 b
Zartman 1967 b

186

Chile

561

22,000

4

189

USA

480

4,528

0

0

520

4,391

9

2.3
0

.29
0
.25

Norigest (200 mg)C
Chinnatamby 1971

15

Sri Lan ka

EI-Mahgoub & Karim 1972

29

Egypt

Kesseru-Koos et al. 1973

74

Peru

Koetsawang 1975

78

Thailand

Rice·Wray et al. 1971

136

Mexico

Zanartu & Onetto 1972

186

Chile

171

4,329

0

2,177

21,730

16

71

648

8

14 .8

112

{ l,069
308

0
0

0
0

130 d

d

.88

2,300

10

92

904

0

0

5.2

Depo -Provera (6 months)e
EI·Mahgoub et al. 1972

31

Egypt

76

Pakistan

145

1,673.5

5

3.6

Mackay et al. 1971

105

Austral ia

61

989

0

0

Nunez 1971

123

Honduras

300

2,385

Schwallie & Assenzo 1972

149

USA & Latin America

991

21,470

31

1.73

Zanartu & Onetto 1972

186

Chile

1,099 1
598 9

43,387
20,387

54
28

1.4
1.6

Khan et al. 1973

.5

aCalculated by Pearl formula (pregnancie s per 100 woman-years of usel.
bParticipated in Upjohn cooperat;ve study . Data on all women (except Soichet 1969 (157),51 women) also reported by Schwallie &
Assenza 1973 (150).
eOose VIlas 300 mg except as noted.
clnJectlon Interval was 84 days except as noted
d'njection interval was 90 days .
IDose was 250 mg.
90 ata also reported by SchVllallie & A ssen zo 1972 (1491.
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run, they frequently disturb menstrual patterns, some
times severely, and Depo-Provera may also cause weight
gain.

45
40
35

Menstrual Cycle Disruptions

30

All progestogens, but especially the injectables, disrupt
menstrual patterns. Women using injectables may experi
ence shorter or longer cycles, increased or decreased
menstrual flow, and spotting . Many women tolerate these
disturbances, but others do not . Menstrual disturbances
cause more women to discontinue injectables than does
any other side effect. Therefore, supplemental estrogens
are sometimes used to regulate menstruation .
The injectables have their most unpredictable effects on
menstrual patterns during the first months of use. Dis
cernible menstrual cycles may disappear entirely, to be
replaced by intermittent bleeding and spotting of unpre
dictable duration, interval, and rate of flow. If identifiable
cycles continue, their length may vary widely from month
to month and from one woman to another. In a few
women, injectables immediately bring on amenorrhea. In
many Depo-Provera studies fewer than half the users
experienced "normal" menstrual flow following a first
injection (2, 23, 81, 101. 149, 150). Irregular bleeding
often gives way to amenorrhea which may then continue
as long as the drug is used . By the end of two years, 40
percent or more of Depo-Provera users may be amenor
rheic (23, 81) (see Fig. 3).
Researchers who have studied both injectables suggest
that Norigest disturbs menstrual patterns less than Depo
Provera (29, 74, 185). But comparing separate studies of
the two injectables is difficult because of differing defini
tions of normal menstrual patterns and differing methods
of aggregating data. While more and more Depo-Provera
users experience amenorrhea as usage continues, Nori
gest users appear to experience an increasing proportion
of normal cycles as time passes (29, 144) (see Fig. 4). This
observation may be biased, however, by the fact that
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Fig. 3. Percentages of women experiencing various
bleeding patterns while receiving three-month injections
of Depo-Provera (150 mg).
SOURCE: Adapted from Koetsawang et al (81)

women with disrupted menstrual patterns are more likely
to abandon the method than are women with normal
cycles.
Management of Bleeding
Orally administered estrogens are often used to treat
menstrual disturbances caused by injectable progesto
gens. At first the estrogens suppress menstrual bleeding .
Then, when they are withdrawn and estrogen levels drop,
withdrawal bleeding, which may be similar to normal
menses, usually occurs . Thus, cyclic administration of
estrogens can be used to treat excessive bleeding, irregu
lar bleeding, or amenorrhea.
Various estrogens have been used in different regimens,
ranging from a full cycle of oral contraceptives (23) to a
single 10 mg injection of long lasting (depot) estrogen (93,
136) to 1 mg or less of oral estrogen daily for several days
each month (9, 24, 29, 67, 84, 91, 101 , 122, 129, 136,
154, 184). Supplemental estrogens have been adminis-

Table 2-Effectiveness of Depo-Provera in Selected Studies by Life Table Method l , 1972-1974

Author & Date
of Publication

Reference
Number

Area

Pregnancies per 100 women

Number of Women
Starting Use

Year

Year
2

Year
3

Year

Year

4

5

THREE MONTH
DOSE (150 mg)
McDaniel et al.

103

Th ailand

9,284

In Each Year:
Cumu lative :

150

USA & Latin
America

3,857

In Each Year :
Cumulative

.31
.31

.26
.53

In Each Year :
Cumulative:

.5
.5

.3
.8

In Each Year:
Cumulative :

.7

.7

1974

Schwallie &
Assenzo

1.0
1.0

.4
1.4

0
1.4
.37
.90

0

0
.90

.90

1973

Zanartu & Onetto

186

Chile

561

1972

0

0
.8

.8

.9
1.6

.8
2 .4

.2
2.6

SIX MONTH
DOSE
McDaniel &
Pardthaisong
1974 (400 mg)

101

Schwallie & Assenzo
1972 (300 mg)

149

USA & Latin
America

991

In Each Year:
Cumulative:

2 .28
2.28

1.34
3 .6 2

1.06
4.68

.57
5.25

Zanartu & Onetto
1972 (300 mg)

186

Chile

598

In Each Year :
Cumulative :

1.8
1.8

1.3
3.1

1.2
4 .3

.6
4.9

Thailand

1,132

.6
3.2

lThe life table method measures pregnancy rates per 100 women in a specified time period of contraceptive use.
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tered either routinely, in response to a patient's request or
complaint, or when indicated by objective criteria such as
heavy bleeding. McDaniel has suggested the following
indications for the use of supplemental estrogens with
Depo-Provera:
• prolonged spotting (more than 7 days in 28)
• heavy bleeding (more than was usual before injec
tions began)
• more than 7 days bleeding
• any bleeding which is or could become a source of
progressive anemia
• three or more months of amenorrhea, if it is disturb
ing to the woman (91).
Other conditions, such as pelvic infection, cervicitis, malig
nancies. moniliasis, or tricomoniasis, may also produce
menstrual disruption. Clinicians should therefore ensure
that these conditions are absent before blaming the injec
table (9).
Although he has suggested specific indications for the use
of supplemental estrogens, McDaniel himself administers
them routinely to all his patients in the McCormick Hospi
tal Family Planning Program in Chiang Mai Province,
Thailand. He does so in an attempt to provide women with
the reassurance of at least one withdrawal bleeding be
tween injections and to prevent the rare occurrences of
heavy bleeding which would require immediate medical
care difficult to obtain in rural areas (52).
If oral estrogens are used in conjunction with injectable
progestogens, some women may consider the method not
much more convenient than taking standard oral contra
ceptives (24, 67). This objection may be largely overcome
by the administration of a single dose of long acting oral
estrogen, such as quinestrol. given monthly or at the time
of injection, as is currently done in the McCormick Hospital
program (94). Despite the fact that estrogens sometimes
cause side effects such as nausea and dizziness, the
advantages of a regular menstrual pattern outweigh the
disadvantages of estrogenic side effects for some women
(155). Also, the advantages of complete protection for a
three-month interval may outweigh the apparent incon
venience of using both oral medication and injections. Fur
thermore, the woman who fails to take her oral estrogen
supplement does not increase the risk of pregnancy as
does the woman who fails to take an oral contraceptive
tablet (24, 91).
Several researchers have studied either Depo-Provera or
Norigest combined with a long-lasting injectable (depot)
estrogen-for example, 25 mg medroxyprogesterone ace
tate with 5 mg estradiol cypionate (17, 78) or 50 mg
norethindrone enanthate with 5 mg estradiol undecylate
(66). These combination injectables, administered
monthly, produce fewer menstrual pattern disturbances
than the higher-dose, longer-lasting progestogens alone .
No pregnancies have been reported with these combina
tions, but experience is still very limited.

Weight Gain
Weight gain, which may be an advantage to some and a
disadvantage to others, occurs ina majority of Depo
Provera users (2,46. 87, 122, 141,155). In clinical studies
mean weight gain has ranged from 1.4 pounds (141) to 9
pounds (155) in the first year of Depo-Provera use. Some
K-6
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Normal cycles
(1 to 7 days

90

bleeding at 26
35 clay intervals)

80

Long Of short
cycles

70
Amenorrhea

60
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10

Year 01 Use

Fig. 4. Percentages of menstrual cycles of various types
in Peruvian Norigest users with previously normal men
strual patterns, by year of Norigest use .
SOURCE: Adapted from Schering AG (145).

researchers find that weight gain levels off after the first
year (15, 46, 190). Others report a slow and continuing
increase (141, 150). McDaniel et al.. studying 800 Thai
women who used Depo-Provera for 30 months, found that
mean weight gain at the end of 12 months was 2.8
pounds; at 24 months, 5.1 pounds; and at 30 months, 5.4
pounds (103). Which women will be affected is not predic
table, although obese wcmen may gain less than others
(87).
In some parts of the world weight gain is actually an asset
(3, 16). Apelo et al. report from the Philippines that:
Weight gain did not prove to be a problem because this was
usually welcomed by most women, especially those who
belonged to the lower socioeconomic group. A gain in
weight, to them. connoted tolerance to the drug and they
felt happy about it (3).

Carbohydrate Mt;tabolism
Depo-Provera may have some effect on carbohydrate
metabolism, although this relationship has not been def
initely established. Some researchers find that Depo
Provera raises glucose levels in the blood (13, 39, 114,
160); others report that it does not (30, 150, 165, 167,
171 ).
The clinical issue at stake in the debate over carbohydrate
metabolism is whether diabetics and pre-diabetics should
use Depo-Provera. If Depo-Provera does raise blood glu
cose levels, diabetics and pre-diabetics may not be able to
produce the additional insulin necessary to metabolize the
extra glucose (39). Since diabetics and pre-diabetics face
higher risks during pregnancy, their need for effective
contraception is great. Close medical supervision during
their use of contraception is necessary.
Progestogen-only minipills do not seem to interfere with
carbohydrate metabolism (133). No changes in carbohy
drate metabolism have been reported in women using
Norigest (29, 40, 184).
Other Side Effects
Other complaints reported by users of injectables include
nausea, dizziness. headache, nervousness, chills, change
in skin pigmentation, galactorrhea, painful menstruation,
lessening of libido, diminished orgasm, and acne. How

often non menstrual side effects occur and what proportion
of users experience these often highly subjective symp
toms vary from one study to the next. In the Upjohn
Company's cooperative studies of Depo-Provera, Schwal
lie and Assenzo reported that nonmenstrual side effects
other than weight gain were similar in type and frequency
to those reported by users of oral contraceptives (149,
150). On the other hand, Scutchfield and his associates
found that, in a Georgia (USA) family planning clinic, the
side effects among Depo-Provera users paralleled those of
IUD users rather than those of orals users (154). Larranaga
and Kesseru have commented that there are fewer non
menstrual side effects with Norigest than with orals (86).
Injectables might be expected to cause fewer nonmen
strual side effects beca use they do not contain estrogen,
which has been blamed for nausea, dizziness, and head
ache associated with combination oral contraceptives (22).

for at least one year (see Table 3). Continuation rates are
influenced not only by the characteristics of the contracep
tive method but also by the age and parity of the user,
social and cultural attitudes, accessibility of services,
availability of alternate methods, and other factors. There
fore, comparisons among studies are difficult to make.
Researchers who have compared continuation rates for
different contraceptive methods in similar patient popula
tions have found that the continuation rate for Depo
Provera was higher than that for orals but lower than that
for IUDs (3,95,154) (see Fig. 5). Doctors at a clinic in Egypt
report that the continuation rate for Norigest was higher
there than rates both for IUDs and for orals (29).
Among side effects of Depo-Provera, excessive and irregu
lar menstrual bleeding or spotting can be blamed for the
largest proportion of discontinuations-between one
quarter and one-half of all first-year drop outs. Amenor
rhea is responsible for about 10 percent of discontinua
tions (see Table 4) . Menstrual disturbances caused by
Norigest, because they are less severe than those due to
Depo-Provera, apparently cause fewer discontinuations,
though reports are few . In the Peruvian field trials of
Norigest, by the end of two years 5.5 percent had dropped
out because of menstrual disturbances, most of that in the
first year. Some 87 women discontinued Norigest because
of amenorrhea; 15, because of spotting or breakthrough
bleeding (74).

With the possible exception of weight gain in Depo
Provera users, clinicians have not observed symptoms of
metabolic or endocrine changes among users of injec
tables. Most field trials have yielded no clinical evidence
that the injectables adversely affect blood clotting, adrenal
or liver function, blood pressure, or lactation, all of which
are affected to some degree by estrogen-progestogen
contraceptives. Nor have laboratory studies produced any
conclusive evidence of adverse metabolic or endocrine
effects.

Women may find menstrual disturbances upsetting be
cause they think that irregular or excessive bleeding is a
symptom of sickness or that amenorrhea is a sign of
pregnancy. Religious practices, folk beliefs, and rumors
may also contribute to a woman's concern. For example, in
Egypt, investigators have reported that :

CO NTINUATION
Despite the side effects of injectables, 60 percent or more
of all users can be expected to continue with the method

Table 3-Percentage of Women Continuing Use of Depo-Provera or Norigest by Months of Use in Selected Studies, 1970-1974

Author & Date

Reference
Number

Country

Number of
Women

Percentage of Women Receiving Next Injection
by Months of Use

Dose I nterva I
in Months
3

6

92

81

9

12

15

18

24

36

48

38

60

DEPO-PROVERA:

72

3

Phil ippines

226

3

Dodds 1971

23

Hong Kong

1,883

3

Khan et al. 1973

76

Pakistan

145

6

Koetsawang et al.
1974

81

Thailand

886

3

76

60

46

McDan iel er al.
1974

103

Thailand

9,284

3

74

59

48

McDaniel &
Pardthaisong 1974

101

Thailand

1,132

6

86

78

67

55

46

McDaniel &
Pardthaisong 1973

102

Thailand

217
108

3
6

79

69
69

64

60
60

McDaniel &
Pardthaisong 1972

95

Thailand

2,967

3

89

78

69

62

22

Apelo er al. 1974

63

61
54

60
48

41

34

55

26

48

Schwallie &
Assenzo 1973

150

USA & Latin
America

3,857

3

59

42

30

24

Schwallie &
Assenzo 1972

149

USA & Latin
America

991

6

67

42

27

14

Scutchfield 1971

154

USA

723

3

Sin er al. 1973

156

Malaysia

550

1-6

Zartman 1970

190

USA

478

3

74

Peru

1,844

76

57

49
41

63

77

93

NORIGEST:
Kesseru-Koos
et al. 1973

84 days

86

75

69

66
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For many women this unpredictable menstrual behavior
was disturbing as they feared that amenorrhea may indi 
cate pregnancy or they believe that retention of menstrual
blood has a serious toxic effect on the body. Spotting is
troublesome as it compels our cases to prohibit intercourse
due to religious habits; mild or excessive bleeding is most
alarming (67)

Pl!!rC*lI

20

Bantu women believe that amenorrhea means blood will
collect in the head, causing headaches (68) . In Chiang Mai
Province, Thailand, the rumor once circulated that amen
orrhea leads to insanity (95).

Educating and reassuring women about menstrual dis
turbances can promote continuation of the method. In
Mexico, Rice -Wray and her associates
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If such fears can be eliminated, many women will tolerate
amenorrhea. That a woman's psychological well-being
depends on regular menstruation may be, as Molitor puts
it, "a somewhat masculine idea" ("une idee un peu
masculine") (113). Poor nutrition and short birth intervals
in developing countries may make regular menstrual
patterns the exception rather than the rule . Clinicians from
various areas report that many women actually are
pleased by the absence of menstruation (81, 84, 113).
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Fig. 5. Percentages of women continuing various contra
ceptive methods in three clinic programs, 1971-1974.

portion of discontinuations among users of injectables.
Only 1 .1 percent of the women in the Peruvian field trials
abandoned Norigest because of nonmenstrual side effects
(74). In most large studies of Depo-Provera, less than six
percent discontinued because of nonmenstrual complaints
other than weight gain (16, 81, 104, 149, 150).

have found that the continuation rate depends largely on
the confidence the patient has in the doctor and the
expla nation she received (136) .
Zanartu, in Chile, has recommended group instruction
about menstrual disturbances (186), and Chinnatamby,
from Sri Lanka, has stressed the importance of repeated
assurances (16).

Among non menstrual side effects of Depo-Provera, weight
gain is sometimes a reason for discontinuation, but, be
cause the gain usually is moderate, it is not a major cause
of dropouts. For example, in the Upjohn Company's coop
erative studies, involving mainly US women, it caused only
1.7 percent of the participants to discontinue (149).

FERTILITY-RELATED EFF ECTS

Return of fertility may be delayed for several months or
longer after discontinuing use of an injectable. This effect
is more frequent and longer lasting with Depo-Provera
than with Norigest. In addition, various progestogens may
be associated w ith virilization and an increase in congeni
tal defects among the offspring of women who receive the
drugs during early pregnancy .
Return of Fertility

Various other nonmenstrual symptoms, including those
subjectively determined, are responsible for a small pro

A study of 114 women who discontinued Depo-Provera in
order to become pregnant showed that median time to

Table 4-Percentage of Women Discontinuing Use of Depo-Provera for Menstrual Disturbances
by Years of Use in Selected Studies, 1970-1973
Percentage Discontinuing
Author & Date
of Publication

Reference
Number

Country

Number of Women
Starting Depo-Provera

For Amenorrhea
1 year

2 years
9

Dodds 1971

23

Hong Kong

1,883

6

Jeppsson 1972

61

Sweden

139

2

Khan et al. 1973

76

Paki stan

145

McDaniel &
Pardthaisong 1973
3 month regimen
6 month regimen

102

Thailand

Scutchfield

154

USA

Sin et al. 1973

156

Malaysia

550

Zartman 1970

190

USA

478

For Excess or
Irregular Bleeding
1 year

2 years

13

17

1 year
39

2 years
52

42

14
24

For All Reasons

24

59

217 a
108 a

2
7

7
10

40
40

723

3

14

43

74

etal.1971
35

20

59

4

23

apostpartum women. Routine estrogen supplement admini stered after weaning of the infant-u sually at 9-12 months .
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conception was 13 months from the date of the last 150
mg injection, or 10 months from the assumed end of
contraceptive protection. By comparison, median time to
conception after discontinuing IUD or diaphram contracep
tion is two months. However, by 18 months after discon
tinuation cumulative conception rates become similar
regardless of the method previously used (151) (see Fig. 6).
McDaniel. using 15 weeks after the last injection as the
discontinuation point, reported that 76 .8 percent of 135
women were pregnant within one year (97). He compared
this to one year cumulative conception rates of 94 percent
for oral contraceptives (142) and 88 percent for IUDs (1 62).
By 14 months, 82 percent of the former users of Depo
Provera were pregnant.

Fertility returns more quickly after Norigest use. Zanartu
has estimated that conception is likely to occur three to six
months after the last Norigest injection (182, 183). A study
of 48 women who discontinued Norigest found that 15, or
31.3 percent, became pregnant within six months after the
last injection (74). While a quicker return of fertility may
make Norigest more acceptable than Depo-Provera for a
woman who wants more children, it may also mean an
unplanned pregnancy for a woman who is even a few days
late receiving her next injection.

The duration of infertility after discontinuation of Depo
Provera apparently bears no relationship to the length of
time the injectable is used (23, 95, 150, 151), but rather
may reflect individual differences in the rate of drug
absorption and excretion (151, 174). Women with lower
body weights tend to conceive sooner after discontinuing
Depo-Provera (151).

Suspicion that Depo-Provera may cause permanent infer
tility has been a major impediment to its wider use. But,
despite the importance of the issue, little research has
been conducted on it, possibly because of the difficulty of
confirming infertility or determining its causes . Thus, it is
not possible to estimate what percentage of women may
be affected or even to state firmly that Depo-Provera does
cause infertility. Ovulation-stimulating drugs have been
used successfully to return fertility after Depo-Provera
injections (140), implying that no damage to the reproduc
tive system had occurred.

nancy tests are especially implicated (60, 69, 117, 118,
119, 120). The risk is small-probably no greater than 7
per 10,000 births (85)-and probably occurs only in con
junction with "some type of maternal predisposition" (118).
In an attempt to avoid administration during pregnancy, the
first injection of Depo-Provera or Norigest is usually given
withi n a few days after menstruation.

DEBATE OVER CANCER RISKS

Suspicion that Depo-Provera might stimulate certain can
cers has repeatedly delayed approval' of the drug in the
USA. A controversy over whether the injectable increases
the incidence of cervical carcinoma in situ, a possible
precursor of invasive cancer, is still unresolved. Several
years ago researchers found that both Depo-Provera and
Norigest produce breast nodules in certain test animals.
Subsequently, however, many scientists have concluded
that the results of these animal studies cannot be extrapo
lated to humans.
Cervical Carcinoma in Situ
Some statistics suggest. but do not prove, that cervical
carcinoma in situ may occur more often among Depo
Provera users than among nonusers. Among 10,333
women who used the injectable for a total of 14,891
woman-years, 35 cases of carcinoma in situ were reported
(152), but because there was no control group in this
study, it is difficult to evaluate these data (44).

An attempt has been made to compare the rates found
among Depo-Provera users with age and race adjusted
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Fetal Effects
In the late 1950s and early 1960s researchers discovered
that some progestogens, when given in early pregnancy,
occaSionally cause masculinization of the external geni
talia of female fetuses (1, 127, 179). In most of these
cases, progestogens were given in large doses to prevent
threatened or habitual abortion. In large doses medroxy
progesterone acetate (the active ingredient in Depo
Provera) virilizes rat and rabbit fetuses (107, 127), but no
such effect on human fetuses has been reported, either
with doses of Depo-Provera as high as 400 mg (41) or with
Norigest.
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Diaphragm, condom, other traditional
contraceptives; data rejlorted 1950 (163),
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35

Months Aher Discontinuation or last Injection

Recent reports have suggested that in a few women
steroids administered in early pregnancy may cause con
genital anomalies. Progestogens administered for preg

Fig. 6. Cumulative conception rates for women who
discontinued Depo-Provera to become pregnant, com 
pared with cumulative conception rates for former users
of IUDs and of traditional contraceptives.
SOURCE : Adapted from Schwallie & Assenza (151).
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carci noma in situ rates from US surveys conducted by the
National Cancer Institute (NCI) (152). Such a comparison
between separate studies, however, leaves a wide margin
for possible inconsistency and bias. Depending on the age,
race, location, regimen, and, to a lesser extent. the statisti
cal method used, rates of cervical carcinoma in situ among
Depo-Provera users range from less than one to more than
nine times the age and race adjusted rates in the U.S.
population (37, 152). For the usual regimen of 150 mg / 3
months, the risk is 1.55 times the adjusted US rate (152), a
difference which is "statistically and clinically insignifi
cant" (44).

US FDA officials, faced with the problem of how to interpret
the inconclusive statistics, twice nearly approved Depo
Provera for contraceptive use and twice withheld approval
because of objections from Representative L. H. Fountain,
chairman of a congressional subcommittee concerned
with intergovernmental relations. It was Fountain who,
in 1974, first made an issue of the apparently higher inci
dence of carcinoma in situ among users of Depo-Provera .
He has argued that the statistics raise enough doubts
about the safety of the injectable to justify keeping it off
the market (37) .

Responding to Fountain's objections, the USFDA exam
ined the data, and it concluded that no increased risk could
be proved. The agency pointed out that almost all of the
carcinoma in situ cases among Depo-Provera users oc
curred within the first two years of drug use:
From all that we know about carcinogenesis, ... such early
tumors cannot be considered as drug related ; the absence
of a lag time of 3 to 10 years or more is at variance with the
known toxicological behavior of chemical carcinogens
(146)

The USFDA also argued that the statistics about Depo
Provera raise no more concern than has been raised about
the possible carcinogenicity of oral steroidal contracep
tives already marketed with USFDA approval (146, 147).
Despite these arguments, further protests from Fountain
led to another postponement of USFDA approval. which,
as of March 1975, remains in effect. The agency will hold
an open hearing in April 1975 to discuss the carcinoma in
situ issue with experts on "contraception, epidemiology,
and carcinogenesis" (147).
Only two studies of cervical malignancies among Depo
Provera users have been conducted with control groups for
reliable comparisons, and both were too small to be
statistically significant. A Chilean study found no differ
ence in the rates at which cervical growths occurred in
Depo-Provera users and in IUD users. But, for unknown
reasons, women who chose the injectable were more
likely to have a cervical malignancy before beginning
contraception than were those who chose the IUD (18). In a
Belgian study which included Depo-Provera, abnormalities
and malignancies, as determined by Papanicoulau cervical
smears, occurred less than half as often among the users
of continuous progestogen contraception as in a control
group using no hormonal contraception (54).

Papanicoulau smears taken during the Peruvian field trials
of Norigest produced no evidence that the injectable in-
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creased the incidence of cervico-vaginal abnormalities
(75) .

It has been hypothesized that continuous progestogen
contraception would be more likely to stimulate carcinogen
esis than cyclical combined estrogen-progestogen con
traception because an unchanging hormonal environment
might encourage mutant cells to multiply unchecked,
whereas a changing hormonal environment might check
this growth (124, 135). This has not been proved, how
ever .

Breast Nodules and Cancer
Depo-Provera causes breast nodules in beagles . Norigest
causes breast nodules in rats and mice, as do other
nortestosterone derivatives. But no evidence suggests that
the injectable progestogens have the same effect in
women, and the applicability of the animal study results to
humans is disputed.

Studies conducted by the USFDA in the late 1960s found
that female beagles receiving the body weight equivalent
of the human contraceptive dose of Depo-Provera devel
oped persistent breast nodules (175) and beagles receiv
ing 25 times the equivalent human dose developed malig
nant nodules and metastases (36). As a result, in 1970 the
Upjohn Company withdrew from the market Provest, a
combination oral contraceptive which contained medroxy
progesterone acetate. Chlormadi none acetate, another
progesterone derivative studied as an injectable and at the
time used in some oral contraceptives, was also removed
from the market because it had a similar effect. The USFDA
allowed clinical trials of Depo-Provera to continue, how
ever, reasoning that other effective oral contraceptives were
available but that Depo -Provera appeared to be the only
highly effective injectable (8, 36).

The results of the beagle studies renewed the ongoing
controversy over the extrapolation of animal study results
to humans. Some researchers argue that dogs, particularly
beagles, react differently and are more sensitive to proges
terone and progestogens than are women and usually
develop a type of breast nodule rarely found in women (14,
115, 116, 169, 175). They also point out that primates
given Depo- Provera have not developed breast nodules, to
which the USFDA replies that monkeys are more resistant
to breast nodules than women are (8, 36).

The only study which compared the incidence of breast
nodules in Depo- Provera users with incidence in controls
found no significant difference between the two (98).
McDaniel, who conducted the study with 1,270 users of
the injectable and 257 controls, called the beagle experi
ments "unfortunate and misleading ."

After Norigest was discovered to cause pituitary and breast
nodules in rats, Schering AG stopped clinical trials (116)
and removed the injectable from the market in Peru, the
only country where it was available commercially (25).

Later studies revealed that in rats Norigest has strong
estrogenic effects, rather than the progestational effects it
has in rabbits and humans. Schering scientists postulate
that this estrogenic effect in rodents causes pituitary
proliferation and tumors and increases the secretion of
prolactin by the pituitary. The increased prolactin overstim
ulates mammary growth and triggers the development of
mutant cells. Because of species differences this does not
occur in humans (116). To varying degrees, other nortes
tosterone derivatives also cause breast nodules in rodents.
Because rodents appear to be inappropriate test animals,
the USFDA has been willing to approve for human contra
ceptive use nortestosterone derivatives which have slight
tumorigenic effects on rodents.

Fig. 7. Advantages and Disadvantages of Injectable
Progestogens Compared to Oral Contraceptives and IUDs.
Advantages of Injectables
Compared to Orals
• More convenient to use. No
dailY pill taking .
• Freedom from fear of forget
ting.
• No inhibition of lactation.
• No estrogen side effects or
possible long-term hazards of
estrogen .
• Husband
with use.

USFDA officials defend the agency's general reliance on
animal studies with the rationale that, while evidence of
tumorigenic effect in animals does not mean the drug will
cause tumors in hu mans, evidence that it is not tu morigenic
in animals allows a drug to be marketed with "a certain
measure of assurance" of its safety for humans (8). They
emphasize, however, that the agency's decisions are
based on US conditions which may not apply in other
countries:
The risk-to-benefit principle alone is bound to vary from
country to country, requiring variations in interpretations of
results obtained in tests for toxicology, carcinogenicity and
other mUlti-phased complexities arising from such investi
gations. Different interpretations and their consequent
utilization by different agencies in different countries ...
must be made by the responsible agencies on their merits
for prevailing conditions and in the best public interest (8).

PROGRAM ISSUES

The advantages of injectable progestogens-effectiveness,
convenience, ease of administration, and lack of inhibition
of lactation-make them popular with a large number of
both users and clinicians. Nevertheless, the place of
injectable progestogens in a comprehensive family plan
ning program has not yet been fully determined. With
lactating women or women whose families are complete,
injectables may be both popular and appropriate, but, from
the program planner's point of view, the overall effect
could be the substitution of injectables for IUDs or sterili
zations. With nulliparous women or those who want more
children, many family planning officials still urge caution
and limit the use of injectables.
Advantages.
From the users point of view, injectables are attractive.
Reports from family planning programs around the world
show that, where women were offered a choice among
contraceptive methods which included an injectable, be
tween one-quarter and three-quarters chose the injectable
(51, 74, 90, 125, 155, 172). Effectiveness, convenience,
freedom from fear of forgetting (94), and the fact that
husbands cannot interfere with its use (125) are major
reasons for the popularity of the injectable (see Fig. 7). The
mode of administration is also an asset. The attitude
McDaniel and Pardthaisong found in Thailand holds true
elsewhere as well (17, 51, 136):

cannot

Advantages of Injectables
Compared to IUDs
• More effective.
• No pelvic examination or in
sertion procedure necessary .
• No risk of IUD side effects
such as pain, perforations, or
infections.
• Heavy bleeding less frequent .

interfere

Disadvantages of I njectables
Compared to Orals

Disadvantages of Injectables
Compared to IUDs

• Cannot be immediately with
drawn if harmful or distress
ing side effects occur.

• Need to return periodically
for injections.

• Greater possibility of dis
turbed menstrual patterns.
• Possible delay in return of
fertility.
• Self-administration not prac
tical .

• Possibil ity of disturbed men
strual patterns.
• Possible delay in return of
fertility .
• Carcinogenic issues still un
resolved.

. .. since the turn of the century, medicines given by
needle and syringe have been widely regarded as more
reliable, more effective, and more prompt in their actions
than medicines taken orally. In the minds of many of the
common people, a physician without a syringe is not a real
physician at all , no matter how high his degree or other
qualifications may be. Therefore a contraceptive to be taken
by injection has a tremendous advantage over other meth
ods (95).

An important advantage is that injectables do not inhibit
lactation (43, 65, 183), as the estrogen-progestogen oral
contraceptives sometimes do (10, 79, 82). In fact, the
injectables may actually increase both the duration of
lactation (43, 45) and the volume of milk (47, 65, 80). They
are therefore preferable to oral contraceptives for postpar
tum use, especially in countries where mothers breastfeed
their children for long periods (47).

An effective steroidal contraceptive which does not reduce
lactation is welcome for two reasons. Firstly, in the post
partum period women are highly motivated to accept
contraception (191 , 192). Secondly, contrary to popular
thought, ovulation and conception can occur before the
end of lactation amenorrhea (170). Furthermore, in areas
where a woman 's only access to medical care and advice
is during childbirth, a single injection at that time can
provide her with several months of protection against the
next pregnancy (76). In an extensive review of the duration
and contraceptive effect of lactation, Dr. Franz Rosa of the
UN Fund for Population Activities (UNFPA) has recom
mended that progestogen-only contraceptives be provided
to lactating women at least until menstruation recom
mences (138) .
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Whether injectable progestogens alter the composition of
breast milk is uncertain. While one research group found
no significant differences in specific gravity, protein con
tent, and fat content between the milk of Depo-Provera
users and that of controls (80), another group reported
significantly higher milk protein levels and decreased milk
lipid and lactose levels (47). The injectable progestogens
apparently do not affect the immunologic powers of breast
milk (27).

Depo-Provera and/or its by-products (metabolites) can be
found in the breast milk of women using the injectable
(78), but whether this can affect an infant has not been
determined. Radioimmunoassays, used to test for the
presence of steroids in breast milk, cannot distinguish
between the drug and its metabolites, and it is not known
whether the metabolites are physiologically active. There
have been no clinical reports of adverse effects on infants
whose mothers were receivi ng progestogens, but addi
tional research is needed on this point.

In a family planning program injectables offer the advan
tage of quick, easy, and infrequent administration. McDan
iel has found that, if a woman returning for an injection
has no complaints, she can be processed in 60 to 90
seconds. This includes time for a short interview with a
d()~lor or nurse-midwife, paperwork, and the injection
itself (95). Dispensing both Depo-Provera and oral contra
ceptives, one of McCormick Hospital's mobile family plan
ning clinics routinely serves 800 women in one day and
1,500 in the next on two stops near Thailand's border with
Burma (93) (see Fig. 8). The six-month regimen saves even
more clinic time and resources, but it provides a woman
less contact with health personnel should questions or
problems arise.

The injectable progestogens can be administered by jet
injector (126, 143), and evidence from animal studies
indicates that use of the jet may reduce the variation from
one woman to the next in the return of fertility after
discontinuation (177). Both Depo-Provera and Norigest
can be stored without refrigeration for up to five years.

Like oral contraceptives, the injectables have a great
potential for wider distribution and use. Paramedical per
sonnel can easily give injections. Dropping the require
ment that a woman have a pelvic examination before
starting an injectable would also broaden its acceptance in
many areas, since some women will refuse to seek contra
ception if pelvic or general physical exams are required
(86, 139). In developing countries the benefits of wider
distribution of both injectable and oral contraceptives,
especially in terms of the potential reduction expected in
maternal mortality rates, outweigh the risks (139) (see
Population Report A-2). For these reasons McDaniel does
not require pelvic exams in his Thailand program.

We feel that furnishing family planning services to a large
number of women, without the ··Iuxuries·· of general
physical and pelvic examinations and cancer detection, is
more important and fruitful than serving a few, and discour
aging many, in an attempt to cling too rigidly to more
academic and professional medical standards (91).
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Fig. 8. Women receive numbered tickets to wait in turn
for Depo-Provera injections or oral contraceptives from
a McCormick Hospital mobile clinic in Chiang Mai Pro
vince, Thailand. (Courtesy of Dr. E. B. McDaniel.)

... But Use Restricted
Despite the advantages of injectables, many family plan
ning officials have been reluctant to permit the unre
stricted use of Depo-Provera. They have been concerned
because the drug could not be withdrawn quickly if a
problem arose, although this has not proved a problem in
actual practice (94). More importantly, they have feared
that Depo-Provera might cause permanent infertility.
There has been no proof that i njectables can cause steril
ity, and, if they do, it occurs very rarely. But officials and
clinicians are aware not only that undesired infertility
could have disastrous emotional and social consequences
for the woman involved, but also that the reputation of a
family planning program and of family planning itself could
be ruined if people thought they had been deceived about
the reversibility of the method. Thus, even in countries
such as Jamaica, Malaysia, and Thailand, where Depo
Provera is now offered through national family planning
programs, restrictions have been placed on its use. In
Jamaica, only women whose families are complete may
obtain Depo-Provera. The World Health Organization
(WHO) has imposed the same restriction on Depo-Provera
supplied by UNFPA. The International Planned Parenthood
Federation (IPPF), though still without an official policy,
unofficially advises its affiliates against giving Depo
Provera to young women with few children (139). In
Nairobi, the Family Welfare Center, which obtains Depo
Provera from IPPF, restricts the injectable to women over
30 with five or more children and to those who, with their
husbands, sign consent forms (51).

In the Thai National Family Planning Program, a woman
using Depo-Provera must have at least two living children
and want no more. If, after using the injectable for ·'a
period of time," she still wants no more children, she will
be urged to discontinue the injectable and to accept
sterilization. The Thai National Ministry of Health hopes
that Depo-Provera, a recent addition to the national pro
gram, will attract new participants to family planning

Table 5-Usage of Depo-Provera Reported by Family Planning Associations Supplied
by the International Planned Parenthood Federation, 1971-74, and Planned IPPF Deliveries, 1975
Usage 1971

Usage 1972

Usage 1973

Estimated Usage 1974

To Be Delivered 1975

Africa

7,140

22,526

106,768

129,130

241,000

Indian Ocean

2,128

9,157

13,030

38,360

77,000

100 a

4,055

7,000

13,000

28,460 b

53,300 c

83,017

161,874

177 ,000

Western Hemisphere

20,331

22,421

35,382

45,932

114,100

Western Pacified

21,519

23,338

23,082

18,000

18,000

79,578

130,842 c

265,334

400,296

640,100

Region

Middle East & North Africa
South East Asia & Oceania

TOTAL

0

aSudan only.
bThailand only.
cApproximate.
SOURCES: IPPF Reports to Donors (56,57,58l.

d Hong Kong only.

rather than draw women away from sterilization proce
dures, the number of which has been rapidly increasing
recently. Depo-Provera is currently available only at Na
tional Family Planning Program hospitals and health cen
ters staffed by physicians-some 300 out of about 4,000
program outlets (180). However, a study has been started
to evaluate the use of auxiliary midwives to prescribe and
administer the drug.

The McCormick Hospital program in Chiang Mai, Thailand,
which was one of the first to offer Depo-Provera, takes a
less stringent approach. The only requirement for new
acceptors of Depo-Provera is that they have demonstrated
their fertility by a previous pregnancy. McDaniel, who
directs the program, reports that this requirement "is only
to protect the reputation of the program from the acci
dental giving of Depo-Provera to an already sterile couple"
(94).

In Malaysia national family planning officials also have
restricted Depo -Provera. The injectable is available
through 10 National Family Planning Board (NFPB) clinics
with attending medical officers to women who have "al
ready demonstrated their fertility" and have completed
their families. The NFPB requires that women receive
physical and pelvic examinations before starting Depo
Provera and checks for breast nodules with every injection.
Also, they must be told individually about all possible side
effects, including menstrual cycle disruption and "possible
infertility" (132).

Had USFDA approval of Depo-Provera gone into effect, it
would have placed special requirements on the use of the
injectable in the USA. I n its approval statement the agency
wrote that Depo-Provera was intended for "those patients
in need of contraception who cannot accept more regi
mented methods or in whom other alternatives are either
contraindicated, unreliable, or otherwise unacceptable ."
Before a woman could have received her first injection,
she would have had to give her consent after reading a
brochure which explained the known and suspected side
effects and risks of Depo-Provera . Also, pharmacies, pri
vate doctors, and family planning clinics would have been
required to report back to the Upjohn Company on their
distribution or use of Depo-Provera. If harmful effects were
later discovered, the company then would have been able

to notify doctors, who in turn would have contacted their
patients (146). Because USFDA approval never took effect,
these requirements were never instituted.

Fig. 9. Partial List of Countries
Where Depo-Provera is Available as a Contraceptive
Through Commercial Channels and/or
Family Planning Programs, 1974-1975
Some countries where Depo·Provera for contraception is
available:
Western Hemisphere:
Argentina
Barbados
Bolivia
Chile
Colombia
Costa Rica
EI Salvador

Grenada
Guatemala
Honduras
Jamaica
Mexico
Panama
Paraguay

Peru
St. Kitts
St. Lucia
St . Vincent
Surinam
Trinidad

Lebanon
Liberia
Leso tho
Malagasy
Mauritius
Nigeria
Rhodesia
Saudi Arabia

Seychelles
Sierra Leone
South Africa
Sudan
Tanzania
Tun isia
Uganda

Middle East & Africa:
Afghanistan
Botswana
Egypt
Gambia
Ghana
Iraq
Iran
Kenya

Far East, South Asia & Pacific:
Bangladesh
Hong Kong
Indonesia
Khmer Republic
Korea

Malaysia
New Zealand
Sabah
Sarawak
Sri Lanka

Philippines
Pakistan
Thailand
Vietnam

Federal Republic of
Germany

Netherlands
Spain

Europe:
Belgium
Denmark

Some countries where Depo·Provera for contraception is not
available:
Brazil
Canada
India

Japan
Sweden
United Kingdom

United States
Venezuela

SOURCES: Heywood (49,50); IPPF (58); Nortman & Hof·
statter (116).

K-13

DISTRIBUTION

Despite caution and restrictions on Depo -Provera , its use
has grown in recent years . At least 10 countries now offer
the injectable in their national family planning programs,
and use for contraceptive purposes has been approved in
64 countries. Two international donor organizations, IPPF
and UNFPA, now supply Depo-Provera, but the US Agency
for International Development (USAID) does not. since it
does not supply drugs which have not been approved by
the USFDA for use in the USA.

IPPF is currently the largest international supplier of
injectable contraception . In 1975 IPPF plans to provide
approximately 640,000 three-month doses of Depo
Provera to family planning clinics in 41 countries (58) . This
could provide one year of contraception for almost
150,000 women (124). Requests to IPPF for Depo-Provera
have grown rapidly over the past several years, both in
terms of the number of programs requesting the injectable
and the amounts requested (see Table 5). The largest IPPF
shipments in 1974 went to Thailand (140,000 three
month doses), Sri Lanka (35,000 doses), Uganda (12,000
doses), Kenya and Costa Rica (10,000 doses each) (58) .

UNFPA began supplying small quantities of Depo-Provera
in 1972. In 1972 and 1973 UNFPA shipments ranged from
220 to 10,000 doses and went to six countries (19). In
1974, at a cost of $.71 (US) per three-month dose, UNFPA
ordered $200,000 (US) worth of Depo-Provera for Thai 
land, $38,000 (US) worth for Jamaica, and $600,000 (US)
worth to be turned over to IPPF for distribution to its
affiliates (19, 137).

UNFPA has set aside a small portion of its 1975 contracep 
tive supplies budget-up to $200,000 (US) out of almost
$4 million-to buy either Depo-Provera or, if WHO gives its
approval, Noristerat (Norigest), depending upon which
manufacturer submits the lower bid price.

The Swedish International Development Authority (SIDA)
has supplied injectable contraception only once, and it

does not plan to do so again because of reservations about
side effects. In 1974 SIDA provided 100,000 three-month
doses of Depo -Provera to Malaysia 's national family plan
ning program (164). In 1975 and coming years, the Malay
sia National Family Planning Board intends to obtain its
supply of injectables from UNFPA (132)

National family planning programs which offer Depo
Provera include those in Jamaica, Guatemala, Thailand ,
Malaysia, Hong Kong, Khmer Republic (Cambodia). Bot
swana, South Africa, Rhodesia, and Uganda . The fees for
injections which these programs charge to users vary. In
Jamaica, for example, injections, like all other contracep
tive supplies, are free . In Hong Kong in 1974 the fee
ranged from no charge to $1.40 (US) per injection, depend
ing on ability to pay. Other fees per injection in 1974,
expressed in US dollars, included : Botswana , $.43 ; Gua
temala , $.50; Khmer Republic, $.30; Rhodesia , $.41; and
Uganda, $ .70 (121) . The new Thai pilot program charges a
service fee of $ .75 for each injection, as does the McCor
mick Hospital program (94).
Total Depo- Provera Sales
Through commercial channels and sales to international
donors, the Upjohn Company has sold close to 11 million
doses of Depo-Provera since 1968. The company's Belg ian
affiliate, Upjohn S. A. Purrs, manufactures the drug for
international distribution . Upjohn affiliates in Colombia,
Mexico, Korea, the Philippines, South Africa, and Argen
tina produce Depo-Provera for use within their own coun
tries but do not ship to other nations. The drug is now com
mercially available as a "contraceptive," "anovulatory
agent," or "anti -conception compound" in 64 nations,
including 19 Western Hemisphere countries, 13 Middle
East countries, 17 African , 8 European, and 7 Far East
countries (49) (see Fig. 9).

Though doubts have clouded the history of injectable
progestogens and important questions remain unan
swered , use of Depo-Provera has grown in recent years .
Barring conclusive proof that the injectables cause cancer,
their use probably will continue growing . In fact. injec 
tables may become the first cont raceptives produced by
modern technology to win acceptance in the developing
countries while lacking approval in most major industrial
ized nations.

BIBLIOGRAPHY

1. AA ASK OG , D. Int ersex conditions m asqueradin g as simple
hypospadias. Birt h Defe cts . Origrnal A rtic le Series 7(6) : t 2- 130
M ay 1971.

hyd roxyproges tero ne 17-acylales; a new cl ass of potent proges
tins . J ou rn al o f the Amer ican Che m ical Soci ety 80 . 2902 , 2905 .
1958 .

V. R.. eds. Seven th W orld Co ngr ess on Fertil ity and Steri lity.
Octo be r. 1971. Am ster dam , Excerpt a M edic a, t 9 71 . (Interna tion al
Congress Series No. 23 4a) p. 85 .

2. APELO, A. and CA NCI O- LOPEZ, F. Cti neie l e:.:peri ence wi th
Depo· Pr over a-a n InjeCtab le con1raceptlve. 196 9. 14 p. (Un pub 
lished)

7. BE DOYA- HEV IA. M ., GA RCIA. M ., and KESS ERU , E. Eff ect s of
various con traceptive agen ts on ovul atio n i nvestigated by mor
phologica l St udyof th e ovary In: Wood, C. a nd Wa lt er s, W . A .• ed s.
Fift h Wor ld Congress o f Gynecology and Obstetrics. Sydney. 196 7.
New York. A ppleton -Cen tury-Cro ft s. 196 7. p. 340.

12. BUR. G. E.. GO NZALEZ· PE NA. J . C.. LU CHETA. M .• and
ANTELO. L. Cambios his topatolog icos de las tro m pas de ' alopi o
durante el trat em ienlo con enantato de no r eti st erona. (H istopath·
olog lcal changes o f t he fall opia n tubes d uring tr ea tme nt w ith
nor ethi st erone enan thetel Obs tetrl cia y Ginecolog la Latino
Ame rica nas 26(1 1/ 12): 494-49 7 . Nove mber 19 70.

3. A PELO, A. A. , De La CR UZ, J R. . and CA NCIO· LOPEZ, F.
Accepta bili ty of injecta ble cont raception In t he Ph il ipp in es. IP PF
M edic al Bullet in 8(2) : ' -2 . Apn l 1974
4 . AReHA Rt. K. Effec t o f no r-ethi steron e ena nlh ,lI e (SH 393) on
t he St r uct ure of the endo metr ium and on the cervica l m ucus.
J ourna l 01 Obstetr ics and Gynaecology of India 19(6) : 73 1-736 .
19 69.
5. A RCHA Rl. K. Inlluen ce o f nor -eth isterone enanthate o n th e
structu re of ovary. pa n ic ular ly corpus l u teum. J ourna l of Ob stet
rics an d Gynaecolog y 0 1 India 20(3)' 39 3·396 1970.

6. BA BCOCK . J . C.. GUTS EL L. E. S .. HER R. M. E.. HOGG. J . A ..
STUCKI, J. C., 8A RNES. L. E., and DULIN, W . E. 6o -met hyl -17a .

K-14

8. BER LI NER , V . A. U.S. Food and Dr u g Ad ministration req uire 
men ts for toxici ty tes ting of contra ceptive products. Act a Endoc rin
olog lca 75 : 240 -265. 1974 .
9 . BLOC H. B. Q.epot madro xypr oges terone aceta te (Depo -Provera )
as a co ntracept ive pre parat ion . Sou th A frican M e(h ca l Jou rna l
4 5(2 8 ): 7 77 ·780 . J uly 17. 197 1.

13 . CAMANNI. F.• M ASSARA F.• and MOUN Anl. G. M . The
cortisone -lik e effect o f 6a-methyl - 17a -acetoxyproges tarone In
the adren alectomized mean . Acta Endocri nologi ca 43 : 477-483 .
1963.

10. BORG UN, N. E. and SANDH OLM. L. E. Elfect of oral cont ra·
cep llves on lacta tion. Fe rtility and Ste r ility 22: 39-4 1. 197 1

14. CA PEL· EDWARDS. K.. HALL. D. E" FEL LOWES. K P.. and
VA LLANC E, D. K. Long ter m admini stra tion o f proges terone ( 0 th e
fema le beagle dog. Toxicology and Applied Ph armacology 24:
474 ·4B8. 197 3.

I 1. BRAT . T. M. A ccep tabI lity o f Depo -Pr over s as a reliab le
co ntr aceptive m eth od. f Abs trac t] In. Kleinm an, R. and Pick les.

15. CHI NNATA MBY, S. A co mpafison 01 the long-a cting cont ra 
cept ive agen ts nore thisteron e oen an th ate and medroxpr oges ter 

one acetate. Australian and New Zealand Journal of Obstetrics
and Gynaecology 11 :223-236 . 1971.

steroid contraceptives over long periods of time. Contraception
2(4): 225-248. October 1970.

16. CHINNATAMBY, S. Long acting injectable-Depo Provera as
a contraceptive. In: Hudono. S. T.. ed. Proceedings of the Fifth
Asian Congress of Obstetri cs and Gynaecology, Djakarta. Indone
sia , October 8-15, 1971 . Djakarta, Sub-committee Publication and
Publicity, Fifth Asian Congress of Obstetrics and Gynaeco logy.
1971 . p. 176-185.

43. GOMEZ·ROGERS, C., IBARRA-POLO, A A " FAUN DES, A,
and GUILOFF, E. Effect of the IUD and other contraceptive meth 
ods on la ctation. In: Hankinson. R. K B., Kleinman, R. L.. Eck 
stein, P., and Romero. H., eds . Proceedings of the Eighth Interna 
tional Conference of the International Planned Parenthood
Federation, Santiago, April 9- I 5, 1967 . London, International
Planned Parenthood Federation, 1967 . p. 328-334.

17. COUTINHO, E. M . and De SOUZA, J. C. Concept ion con trol
by monthly inject ions 01 medroxyprogesterone suspenSion and a
10ng-actlOg oestrogen. Journal of Reproduction and Fertility 15.
209-214. 1968.
lB. DABANCENS , A" PRADO . R . LARRAGUIBEL. R" and ZAN
ARTU, J . Intraepithelial cervical neoplaSia in women using intra 
uterine devices and long-acting injectable progestogens as con
traceptives. Amencan Jou rna l of Obstetrics and Gynecology
119(8): 1052-1056. 1974.
19. DAVID, G. (UNICEF) . Personal communication, Februa ry 19.
1975.
20. DAVIS, M . E. and WIED, G. l. Long-acting progestational
agents. GeburtShilfe und Frauenheilkunde 17( 10): 916-928.
1957.
21. De SOUZA. J. C. and COUTINHO, E. M. Control of fenillty by
monthly injections of a miKlure of norgestrel and a long-acting
estrogen : a prelimmary report. COnlraception 5(5): 395-399.
1972.
22 . DICKEY, R. P. The pill-physiology. pharmacology, and Clini
cal use. In : Isenman, A W., Knox. E. G., and Tyrer, l. B., cds.
Seminar in famil y planning. Chicago, American College of Obste
lricians and Gynecologists, 1972. p. 18 ·40.
23 . DODOS, G. Depoprovera , a repon on the clinical findings and
two year follow up of 1,883 women treated by 3 monthly injec
tions of Depoprovera. In: Hudono. S. T., ed. Proceedings of the
Fifth ASian Congress of Obstetric s and Gynaecology, Djakana.
Indonesia, October 8-15 , 1971 . Djakarta, Sub-commiltee Publlca
lion and PubliCity, Fihh ASian Congress of ObSletrics and Gynae
cology, 1971. p. 169-175.
24 . EI -HA8ASHY, M. A. , MISHELL. D. R" Jr" and MOYER. O. L.
Effect of supplementary oral estrogen on long-acling injectable
progestogen contraception. Obstetncs and Gynecology 35( 1): 51 
54 . January 1970
25. ELLIS. H. L. Personal communication, March 4. 1975
26. EI-MAHGOU8 , S. and AMMAR , R. Ovarian changes during
progestogen amenorrhoea. Journal of ObstetriCS and Gynaecology
of the Briti sh Commonwealth 79 . 841-845. September 1972.
27. EI-MAHGOUB, S. EI-GAMAL, Y" KARIM . M " WI SHAH, A,
HASSAN-ALY, R., and MADIHA, H. Effe cts of injectable proges
[Ogens on the immunologi c power of breast milk . International
Journal of Gynaecology and Obstetrics 10(2): 48-51. March 1972.
28 . El -MAHGOUB, S. and KARIM , M . Depot estrogen as a
monthly contraceptive in nulliparous women With mild uterine
hypoplasia. American Journal of Obstetrics and Gynecology 1 12:
575-576_ 1972
29. EI-MAHGOUB. S . and KARIM, M. The long -term use of
Injectable norethisterone enanthate as a contra ceptive. Contra
ception 5(1 I, 21-29 . January 1972.
30. EI·MAHGOUB, S. E. , KARIM . M .• and AM MAR, R. Long term
effects of mjected progestoge ns on the morphology of human
oviducls. Journal of Reproductive Medicine 8(5) : 28B-292. May
1972.
31 . EI -MAHGOUB. S.. KARIM, S .. and AMMAR. A. Long-term use
of depot medroxyprogesterone acetate as a contraceptive . Acta
Obstetricia et Gynecologica ScandinavlCB 51: 251-255 . 1972.
32 . FINE, L LEVIN, H. M., and M cCONNELL E. L., Jr Masculini
zation of female infants associated with norethindrone acetate.
ObstetriCs and Gynecology 22(2) 210-213. AugUSt 1962.
33. FINE , S. D. Medroxyprogesterone acetete . Drugs for human
use; drug efficacy study Implementation. Federal Regi ster
27(145) : 15033. July 27.1972.
34. FINE: S. D. Medroxyprogesterone acetate for intramu Scu lar
administration . Opportunity for heaflng on proposal to withdraw
approval of peninent parts of new drug application . Federal
Register 38(1951: 27949-27950. October 10. 1973.
35. FINE, S. D. Medroxyprogeslerone acetate for intramuscular
administration . Withdrawal of approval of pertinent parts of new
drug appliclltio n. Federal Register 39(29): 5221 . February 11 .
1974.
36. FINKEL. M . J . and BERLINER, V. R. The extrapolation of
experimental findings (animal to man) the ditemma of the SyS 
temically administered contraceptives. Bull etin of the Society of
Pharmacological and Environmental Pathologists 1(4): 13- 18.
December 1973.
37 . FOUNTAIN , J . H. Personal communication to C. W. Wein
berger, Oelober 2. 1974.
38. GARMENDIA. F.. KESSERU, E. and LLERENA. L. A. Serum LH
concentration In women unde r contraceptive treatment with es
trogen-free progestage ns. Hormone and Met aboliC Research 5 '
134- 138 . 1973.
39. GERSHBERG. H.. ZORRILLA, E" HERNANDEZ, A. , and
HULSE . M . Effects of medroxyprogesterone acetat e on serum
insulin and growth hormone levels In diabetics and potential
diabetics. Obstetrics and Gynecology 33(3): 383-389 . March
1969.
40. GILFRICH, H. J .. NIESCHLAG. F.. DUDECK. J .. and OVERZIER.
C. Norethisterononanthat: Unlersuchungen wahrend der An
wendung eines langwirkenden parenteralen Kontrazeptivum.
[Norethi sterone enant hate: investigatIOns during Ihe use of a long
acting parenteral cOnlraceptive] Deutsche Medlzinlsche Wo
chenschrlft 94(48): 2473-2477. 1969.
41 . GOISIS. M. and CAVALLI , P. The effect on the female foelUs
treatment
with
6-omethyl-17-a-hydroxy
of
prolonged
progrestelone acetate (MAP) during pregnancy . PanmlOerva Med
ica 5(3 / 4): 107- 109 . March-April 1963 .
42. GOLDZIEHER. J . W " KLE8ER , J. W" MOSES, L E" and
RATHMACHER , R. P. A cross-sectional study of plasma FSH and
LH lavels in women using sequ ential , combination or Injectable

44 . GRAY, R. Personal communication to E. B. McDaniel, July 12.
1974.
45 . GUILOFF, E. IBARRA-POLO, A " ZANARTU. J .. TOSCANINI. C"
MISCHLER. J . W .. and GOMEZ -ROGERS , C. EHect 01 contracep
Iton on lactation. Amerrcan Journal of Obstetrics and Gynecology
118(1): 42 ·45 1974.
46. HARNECKER, J " CRISOSTO, C., ONETIO , E" and MUNOZ, L.
Depo-Provera as an injectable female contraceptive agent . [Ab
sHact] In. Proceedings of the SIKlh World Congress on Fertility
and Sterility, Tel Aviv. 1968. Jerusalem, Israel Academy of
SCiences and Humanities, 1968. p. 27-32.
47 . HEFNAWI, F.. FAWZI, G., BADRAWI. M. H" ABDEL-KADER ,
M . M .. and BAHGAT, M. H. Attempt s to select a suitable hor
monal contraceptive during lactation. Paper presenled at the Sixth
World Congress of Obstetrics and Gynecology, New York, April
12·1B, 1970. 17 p.
48 . HEYWOOD, J. T. (The Upjohn Company). Personal communi
cation, September 25, 1974 .
49 . HEYWOOD. J. T. (The Upjohn Company) Personal communi ·
catio n. September 27. 1974.
50. HEYWOOD, J T. (The Upjohn Company). Personal communi 
cation, January 16. 1975.
51. HORNSBY. V. P. l. An experience in family planning in
Nairobi. East Africa Medical Journal 49(10): 714-723 . October
1972.
52. HUBER. D. H. Personal communication. AugUSt 5. 1974.
53. HUBER. D. H. Report of trip to New York, Taiwan. Philippines,
Thailand and London, May 24-June 23. 1974 . Memorandum to
A. T. Ravenholt, July, 1974.
54 . IDE , P., WIJNANTS, P.. and BONTE . J . Observations Cy1010 
giques de trotlis cervlco -vaginaux sous contraception hormonale .
[CytOlogical observations of cervi co-vaginal smears under hor 
mone contraception] Revue de Cytologie Chn ique 5(3): 105-112.
1972.
55 . INMAN, W. H. W " VESSEY, M . P" WESTERHOLM , 8 " snd
ENGELUND, A. Thromboembolic disease and the steroidal content
of oral contraceptives: a report to the Committee on Safety of
Drugs. British Medical Journal 2 : 203-209. 1970.
56. INTERNATIONAL PLANNED PARENTHOOD FEDERATION .
Report to donors' programme development and financial slate
ment s 1971-73. 2 Vols. London , Internali onal Planned Parent
hood Faderation. September 1972. 543 p.
57 . INTERNATIONAL PLANNED PARENTHOOD FEDERATION .
Report to donors' programme development and financial State
ments 1972-74. London, International Planned Parenihood Fed
eration. September 1973.501 p.
58. INTERNATIONAL PLANNED PARENTHOOD FEDERATION.
Repon to donors: programme development and financia l state
ments 1973 -75 . London . Intern ation al Planned Parenthood
Federati on , October 1974. 679 p.
59. JACOBSON. B. D. Hazards of norethindrone therapy during
pregnancy. American Journal of Obstetrics and Gynecology B4(7) :
962 -968 . October 1962
60 JANERICH, D. T., PIPER , J. M., and GLEBAnS, D. N. Oral
contracaptives and congenital limb-reduction effects . New Eng
land Journal of Medicine 291 : 697-700 . October 3. 1974.
61. JEPPSSON, S. Experience with depo-medroxyprogesrerone
acet ate (Depo-Provera) as a contr aceptive agent. Acta Obstetricia
et Gynecologica Scandinavica 51 : 257-263. 1972.
62. JUNKMANN, K. Uber protrahien wirksame Gestagene. [On
the prolonged aClion ofgeslagensJ Naunyn-S chmeidebergsArchiv
fuer ExperimenlelJe Pathologle und Pharmakologie 223: 244·253 .
1954
63 . JUNKMANN. K. and WITZEL, H Chemie und Pharmakologie
von SterOldhormon-Estern. [Chemist ry and pharmacology 01 ste 
roidal hormone eSlers1 Zeitschrih luer Vitamin. Horm on, und
Fermentforschung 9 : 97-143.1958
64. KAPLAN, S. A ., LING , S. M ., and IRANI. N. G. Idiopathic iso
sexual precocity . American Journal of Diseases of Children 116:
591 -598. December 1968.
65. KARIM. M ., AMMAR, R" EI ·GANZOURY. B" FIKRI, F, and
ABDOU, 1. Injected progestogen and lactation. British Medical
Journal 1 200- 203 . January 23 . 1971.
66. KARIM. M. and EI -MAHG OUB, S. Conception control by cyclic
injections of norethisterone enanthale and estradiol unducelate.
American Journal of Obstetrics and Gynecology 1 10(5)' 740- 742.
July 1. 1971.
67 . KARIM , M . and EI-MAHGOUB, S. Inseclable steroidS as a
method of contraception. Ain Shams Medical Journal 21(5): 543
550. September 1970.
68. KARSTADT. 8. InJeCiable long ·actlng progestogen s for contra
ception. South African Medical Journal 44: 480-481 April 18,
1970
69 . KAUFMAN, R. L. Birth defec ts and oral contraceptives.[ Leller
to th e Editor) Lancet 1 (7816): 1396. June' 6, 1973
70. KESSERU-KOOS, E Influence of vanous hormonal contracep
tives on sperm migration in VIVO. Fertility and Sterility 22(9): 584
603 . 1971.
71 . KESSERU-KOOS, E. Recuperacion espermatica intra -cervica l
e Intrauterine bajo tratamienlo can dlversos anticoncePtivos hor
monales e inlrautennos. [Intracervical and intrauterine recovery of
sperm under treatment with various hormonal and intrauterine
contraceptives] In' Calderon, R" Kesseru, E.. and Mondoa, F. , eels.
Simposios del Segundo Congreso Bolivariano de Endocrinologla.
lima, Peru, October 7·10.1969. Lim a, Litografica del Peru S.A ..
1970. p. 120-135.
72 . KESSERU. E. and LARRANAGA, A. Mecanismo de acclon de
los contraceptivos Inyectablesdedeposlto. (Mechanism of action of
injectable depot contraceptives] Ginec ologia y Obstetrlcia (Peru)
14(3),339-359. 1968.

73 . KESSERU, E. and LARRANAGA. A. Method of action of long 
aCling parenleral con traceptive s. In ' Gual, C.. ed. Third Interna
tional Congress of EndOCrinology. MeXICO. June 30-July 5, 1968.
Amsterdam. E;.,c erpta Medica, 1968 . (International Congress Ser
ies No. 157) p. 59 .
74. KESSERU -KOSS, E" LARRANAGA-LEGUIA. A, HURTADO·
KOOS , H .. and SCHARFF. H.-J . Fertility control with norethindrone
enanthale, a long-acllng parenteral progestogen. Acta EurOpae8
Fenilitatis 4(4): 203·221 . December 1973.
75 KESSERU-KOOS, E.. NOACK, P" and LARRANAGA · LEGUIA
A Urinary pregnanediol during the use of diHerent conuaceptive
methods. Acta Endocllnologica Pan americana 2: 73·90. 1971.
76. KHAN. T., KAZI, A. and RAZU . B. Depo-Provera as long-acting
injectable contraceptive In' Proceedings of the Seventh Biannual
Seminar on Research in Populallon PlanOlng, Karachi, April 12-14.
1973. Karachi, National Research Institute of Fertility Control
[1973J p. 97 . 103.
77. KLEINMAN, A. L. ed Systemic contra ceptIon . London. Inter
national Planned Parenthood Federation, 1973 82 p
78 KOETSAWANG, S. Perso nal communication, January 20.
1975
79 . KOETSAWANG, S., BHIRALEUS. p " snd CHIEMPRASERT, T.
Effects of oral contra ceptives on lactation. Fertility and Stenl!lY
23(1): 24-28 . January 1972.
80. KOETSAWANG. S" CHIEMPRASERT, T., and KOCHANANDA
P. The effects of Injectable conH8ceptives on lactation . In : Chnical
proceeding s of Internati ona l Planned Parenthood Federation
South-East Asia & Oceania RegIonal Medical & SCientific Con
gress. Sydney. August 14- 18, 1972. (Sydney 1 Australian and
New Zealand Journal of Obstetncs and Gynaecology (1972] p. 84·
95
81. KOETSAWANG. S" SRISUPANDIT, S" SRIVANABOON, S ..
BHIRALEUS, P.. RACHAWAT. 0 " KIRIWAT. 0 .. and KOETSA
WANG , A. Intramuscular depomedroxyprogesterone acetate lor
cont raception . Journal of the Medical Association of ThaIland
57(8), 396-408 . August 1974.
82. KORA, S. J . Effect of oral contraceptives on la cl8tion . Fertility
and Sterility 20(3): 419-423 . 1969.
83. KUPPERMAN, H. S. and EPSTEIN, J. A. Medroxyproges·
terone acetate in the trealment of constitullonal sexual precosity.
Journal of Clini cal Endocrinol ogy and Metabolism 22' 456-458 .
April 1962.
84 KURREK, H. Depot -ovulationshemmet . (Depot ovulation inhi 
bitors] TherapeuIlsche Umschau/Revue Therapeullque 29 : 307
309. May 1972 .
85. LANMAN. J . T. and JAIN, A. ASSOCiation of oral contraceptives
and congenital limb -reducti on defects. The Population Council,
October 4, 1974 . 4 p. (Unpublished)
86. LARRANAGA, A and KESSERU, E. Dos anos de experiencia
clinice con el enantato de noretisterona como anticonceplivo
inyectable de deposito. [Two years of clinical experience with
noreth,sterone enanthate as an injectable depot contraceptive]
Glnecologia y Obstetricia (Peru) 14(2): 209-221. August 1968 .
87 . LEIMAN , G. Depo-medroxyprogesterone acetate as a contra
ceptive agent : its effect on weight and blood pressure. American
Journal of ObstetriCS and Gynecology 144{l): 97-102 . September
1.1972.
88. UNTHORST. G .. WIBAUT, F P.. and De JONGH. R. E Ervar
IOgen met een 3-maandehjkse injectie medroxyprogesteronace
taat (MPA) als contraceptivum . (Experiences with a 3-monthly
injection of medroxyprogesterone acetate (MPA) as a contraceptive
agent] Nederlands Tijdschrift voor Geneeskunde 116: 1694- 1698.
September 16. 1972 .
89.

un. B. (US FDA). Personal communication. October 10. 1974.

90. McDANIEL, E. B. 1973 annual family planning report, com
bined family planning clin ics in Of under the auspices of McCor
mIck Hospital. ChIang Mal, Thailand. 1974. 4 p. (Unpublished)
91 McDANIEL, E. B. "MinI-manual " for use of DMPA as an
injectable contraceptive. 2nd ed . December 10, 1973 . 12 p. (Un
published)
92. McDANIEL, E. B Personal communication, October 8 . 1974
93 . McDANIEL, E. B. Persona l communication. October 16 . 1974.
94 . McDANIEL. E. B. Personal communication, February 28,
1975 .
95 McDANIEL. E. and PARDTHAtSONG, T. Acceptability of an
injectable contraceptive in a rural populatIOn of Thailand . In
Clinical proceedings of International Planned Parenthood Federa·
tion South-East Asia & Oceania Regional Medical & Scientific
Congress, Sydney, August 14-18. 1972. [Sydney] Australian and
New Zealand Journal of Obstetrics and Gynaecology [1972], p.
BO-B3.
96. M cDANI EL. E B. and PARDTHAISONG. T. Changes in breast
size during prolonged use of contraceptive injections. Journal of
the Medical Association of Thailand 55(5): 294-297. May 1972 .
97 . M<:DANIEL, E. B. and PARDTHAISONG, T. Depot-medroxy
progesterone acetate as a contraceptive agent: return of fertility
after discontinuation of use. Contrac eprion8(5): 407-415 Novem
ber 1973.
98. McDANIEL. E. B. and PARDTHAISONG, T. Incidence of breast
nodules and changes in breast si ze dUring prolonged use of DMPA
Injections for contraceptIon . Paper presented at the 1971 annual
meelLng of the Medical Association of Thailand. Khon Kaen,
Thailand, December 2-4, 197' . 8 p.
99 . McDANIEL. E. B. and PARDTHAISONG, T. Incidenc e of breast
nodul es In women receivi ng multiple doses of medroxyproges·
terone acetate. Journal of Biosocial Scien ce 5(1) ' 83-B8 . 1973 .
100. McDANIEL E. B. and PARDTHAISONG, T. Return 01 men
slfuation and fertility in Thaiwomen after co ntraceptive injectIons.
Journal 01 BiosoCial Science 3(2): 209-222. 1971.
101. McDANIEL, E. B. and PARDTHAISONG, T. Use-effectiveness
of six-month injection s of DMPA as a contraceptive . American
Journal 01 ObStetrics and Gynecology 119(2 ): 175-180. May 15,
1974.
102. McDANIEL, E. B. and PARDTHAISONG , T. Use of a long
acting injectable contra ceptive in a post partum family planning
programme. Asian Journal of Medicine 9: 133- I 35. April 1973 .
103 . McDANIEL, E. B.. PARDTHAISONG. T.. and GRAY. R. The
epidemlotogyof Ihe acceptance and use of Depo-Provera In Chiang

K-15

Mai. northern Thatland. Paper presenled at conference of the
International Epidemiologic ASSOciation , Brighton. United King
dom. August 1974.9 p.
104. McDANIEL. E. B. and ZELENIK, J. S Field tnals results of
long-acting injectable medroxyprogesterone acetate as an injec
table contraceptive in 1,730 patients In : Selected papers on anti
fertility agents, reprinted from Proceedings of the Sixth World
Congress on FertllnyandSterllity, Tel Aviv. , 968. Jerusalem. Israel
Academy of SCiences and Humanities, 1970. p. 13-20.
105 MACKAY. E. V., KHOO. S. K.. and ADAM , R R. Contracep·
tion With a six-monthlY injection of progeslOgen. Part 1. EHect on
blood pressure. body welghl and uterine bleeding pattern, Side
effecls. elficacy, and acceptabilllY. Australian and New Zealand
Journal of Obstelrlcs and Gynaecology 11 148-155. 1971
106. MATHEWS. J. H.. ABRAMS . C. A. and MORISHIMA. A .
PlIuitar)'-adrenal function in ten patients receiVing medroxy·
progesterone acetate lor Irue precocIous puberty. Journal of Clini·
cal Endocrinology and Metabol ism 30' 653-658. May 1970

131. PUGA. J. PUPKIN. M .. ZANARTU . J .. GARCIA-HUIDOBRO.
M ., ROSENBEAG. J .. GUERRERO, R., and SERON. M. Contribution
to study of the main physiological aSDects of the inhibition of
ovulat1On. In ' WOOd, C. and Waiters, W. A, eds. Filth World Con·
gress of Gynaecology and Obstetrics, Sydney, September 1967.
New York. Appleton·CenlUry-Crofts, 1967. p. 247-271.

164 . TRONE , L
1974

133 RAMASWAMY, S. The progestogen-only pill. Medical News
leller (The Family Planning Association), No. 49, July 1973 2 p.

165. TUTILE.
and TURKINGTON , V. E Effects of medro;.r.ypro·
gesterone acetale on carbohydrete metabolism. Obstetrics and
Gynecology 43(5) . 685-692 . May 1974 .

134. RAVENHOLT. R. T. Malignant cellular evolution
117542)' 523-526. March 5. 1975 .

Lancet

135 RAVENHOLT. R. T Oral contraceptives and prevention of
cancer of the uterus and breast. Paper presented al Ihe Sixteenth
International Congress of the International Confederation of Mid 
wives. Washmgton, D.C.. November ,. 1972. 31 p
136. R1CE·WRAY. E.. GUTIERREZ. J .. GORODOVSKY. J .•
MAQUEO, M. , and GOLOZIEHER, J . W . Injectable contraceptives
10 famIly planning' clinicsl experience 10 14,958 cycles . Paper
presented at annual meeting of the Family Planning AssociatIon 01
t he Americas. Inc., Palm Springs. California. November 1971 . 11 p.

108. MISHELL. D. A., Jr . Effect of 6a-methyl - 17a·hydroxy
progesterone on urinary excretion of luteinizing hormone. Ameri
can Journal of Obstetrics and Gynecology 99(1). 86-90 . Septem
berl,1967.

137. RICHMAN . J. (UNICEF). Per sonal communication. Septembel
lB. 1974.

110. MIS HELL. D. R.. Jr.. EI-HABASHY. M . A .. GOOD. R. G . and
MOYER. D. L ConHaceplion with an injectable progestin. Ameri
can Journal of Obstetrics and Gynecology 101. 1046 - 1053. Au
gusl 15, 1968.

138. ROSA, F. The importance of breast feeding to family planning
and suggestions for imprOVing the Interaction . 25 p. (Unpublished)
139. AOSENFIElD . A . G. Injectable long-acting progeslOgen con
traception ' a neglected modality American Journal of Obstetrics
and Gynecology 120(4)' 537·548 . OClober 15 . 1974.
140. ROSENFIELD. A G. Personal communication. February 26.
1975

111. MISHELL. D. R., Jr ., KHARMA. K., and SEWARD, P Expe ri
ence with tri-monthly injection of depo-medroxyprogesterone
acetate as a contraceptive agenl. [Abstract] In: Kleinman. A. and
Pickles. V. R., eds. Seventh World Congress on Fertility and Steril 
Ity. Kyoto, October 17-25, 1971 . Amsterdam. Exce rpla Medica,
1971 (International Congress Series No. 234a) p. 86 .

141. RUBIO, B L, and GONZALEZ. R. A. Contraception With
medroxyprogesterone aceTate: a follow·up study of 1.892 cycles .
In: Selected papers on anti-fertility agentS, repnnted from Proceed ·
ings of the SIxth World Congress on Fertility and Sterility. Tel AvlV.
1968. Jerusalem. Israel Academy of SCiences and Humanities,
1970 p. 21-26 .

112. MISHELL. D. R.. Jr.. TALAS. M .. PARLOW. A. F.. EI ·
HA8ASHY, M .. and MOYEA. D. L. PhYSiologic and morphologiC
alterations effected by the contraceptive use of depo-medroxy·
progeslerone acetate . In: Selected papers on anti·fertllity agents,
reprinted from Proceedings of the SixthWor!d Congress on Fertility
and Sterility. Tel AVlv. 196B Jerusalem, Israel Academy
Sciences and Humanities, 1970 pp. 7-12.

142. SATIERTHWAITE, A. P. Oral contraceptives . In : Berelson, B. ,
ed. Family planning and population programs. Chicago, Unive r sity
of Chicago Press, 1966. p. 411 ·424

0'

113 . MOLITOR, M. P. Commentalfes sur l'utilization du MPA 150
dans un cenlrede planning familial. (Comments on the useol MPA
150 In a famllyplannmg center] 8ulletin de la Societe des Sciences
Medlcales du Grand Duche de Luxembourg 111(1).49-53. Sep
tember 1974.
114. MUGGIA F. M .. CASSILETH. P. A .. OCHOA M .. Jr.. FLA
TOW, F. A., GELLHOAN, A" and HYMAN, G A. Treatment of breast
cancer With medroxyprogesterone acetate. Annals 01 Inlernal
Medicine 68: 328-337 . 1968.
115. NELSON. L. W ., CARLTON. W. W .. and WEIKEL. J . H. , Jr.
Canine mammary neoplasms and progestogens . Journal of the
American Medical Association 219: 1601 ·1606 March 20. 1972.

116 NEUMAN. F.. Von BERSWORDT-WALLRABE. R.. ELGER.
GRAF. K -J .. HASAN. S. H. MEHRING. M .. NISHINO. Y.. and
STEINBECK , H Special problems In tOXICity lesting of long acting
depot contracePtives. Acta Endocrtnologlca 75(185): 315-354
1974.

w..

117 NORA, J. J. and NORA. A. H. Birth defects and oral conlra
ceptlves. (Letter to the Edllor] lancet 1(7810) 941 -942 April 28,
1973.
118. NORA, J. J. and NORA, A H Can the pill causebinh defects?
New England Journal of MediCine 291(14): 731 · 732 . OctOber 3,
1974.
119. NOAA. J J. and NORA, A. H. Oral contraceptives and birth
defects: preliminary eVidence for a possible association. Pediatr iC
Research 7(4) : 321. 1973.
120. NORAA. H. andNORA, J. J . Asyndromeofmultiplecongen 
ital anomatles associated with Teratogenic exposure. Archi ves of
Environmental Health 30' 17-21 January 1975.
121. NORTMAN, O. and HOFSTATIER, E. Population and family
planning programs' a factbook. Reports on Population/Family
Planning. No. 2 (Sixth ed .), December 1974 95 p
122. NUNEZ, J. A Clinical experience wllh medroxyprogesterone
acetate Injected every 3 months . Paper presented at the Sixth
Latin .American Ob·Gyn Meeting, San Jose de Costa Rica, March
29·April 7, 1970. 13 p.
123 NUNEZ. J . A Chnlcal expeflence with medroxyprogeslerone
acetate administered every 6 mth. [Abstract] In: Kleinman. R. and
Pickles. V. R.. eds . Seventh World Congress on Fertility and Steril ·
ity. October, 1971 . Amsterdam, Excerpta Medica, 1971 . (Interna
tional Congress Series No. 234a) p. 85.
124 PAGET -COOKE , S. (IPPF). Personal communication, Septem
ber 6 . 1974
125. PATIERSON. A. W Medroxyprogesterone acetate : a repor!
on len years of use of Depo Provera in family planning programme
in Jamaica . Paper presented at the meeting of the International
Family Planning Research Associat Ion. Palm Spflngs, California .
October 22. 1974 4 p.
126. PATIEASON. A W
1974

Personal communication. October 1,

127 PINCUS, G. The control of fertility New York. Academic
Press, 1965. 360 p.
, 28. pons, M .. Van Der VLUGT, 1.. PIOTROW. P T.. and GAIL.
L. J. BenefIts of orals outweigh adverse effects. Population Report,
Series A. No.2 Washington , D.C., George Washington University
Med ical Center. Population Information Program, March 1975 .
129 POWELL, L. C. and SEYMOUR. R. J. Effects of depo
medroxyprogeslerone acetate as a contraceptive agent. American
Journal of Obstelfics and Gynecology 11 O( 1)' 36-41 . May 1,1971 .
130 PRATI. T. (E . A. Squibb & Sons, Inc.) Personal communlca·
tion, November 26, 1974.

143 . SAXTON. G. A., Jr. A community approach to fenlitY con
trol-the Uganda experience . 16 p (Unpublished)
144. SCHARFF. H . . J .. KESSERU. E.. and LARRANAGA. A Cycle
pallern under the treatment with norethisteronenanthate as a
depot contraceptive . Paper presented at the II Congreso 80livariano
de Endocrinologia , Lima, Peru, October 7 · 10, 1969. 10 p.
145. SCHERING AG . NOflgest injectable contraceptive
Scheri ng AG. October 1973 121 p.

8erlin,

146. SCHMIDT, A. M (USFDA). Patient labeling 01 medroxy
progesterone acetate injeCtable contraceptive Federal Register
39117B): 32907·32911. September 12. 1974.
\47. SCHMIDT. A . M (USFDA). Personal communlcallon to Rep
resentative L.H . Fountain, October 9. 1974. 2 p
148. SCHWALlIE, P. C. Experience with Depo-Provera as an
injectable contraceptive. Journal of Reproductive MediCine
13(3)' 113-117 . September 1974.
149. SCHWALLlE, P. C. and ASSENZO, J . R. Contraceptive use·
elficacy studY utilizing Depo-Provera administered as an Injection
once every 6 months. Comraception 6(4): 315-327 . October 1972
150. SCHWALUE. P. C. and ASSENZO. J. R. Contraceptive use
efficacy study utilizing medroxyprogesterone acetate administered
as an intramuscular injection once ever)' 90 days Fertility and
Sterility 24 : 331-339. 1973.
151. SCHWALLIE. P. C. and ASSENZO , J . R. The effect of depo·
medroxyprogesterone acetate on pltullary and ovarian function ,
and the return 01 fertility following its disconlinuation: a review
Contraception 10(2) : 18'-202. August 1974
152. SCHWALLIE. PC . MOHBERG. N. R.. and ASSENZO . J R
ReView of cervical carcinoma in-Situ associated with the use of
Depo·Provera. June 3. 1974 . 25 p. (Unpublished)
153. SCOMMEGNA A , LEE. A. W .. and BORUSHEK , S. Evalua
tion of an Injectable progestin -estrogen as a contraceptive. Amen
can Journal of Obstetrics and Gynecology 107(8): 1147-1155.
Augu~1 15, 1970.
154. SCUTCHFIELD. F. D.. LONG . w. N.. COREY. B .. and TYLER .
W MedroXYDrogesterone acetate as an IOJectable female conHa·
ceptive Contraception 3(1): 21-35 . January 1971.
155. SEYMOUR , R J and POWELL, l. C Oepo-medroxyproge s
terone acetate as a contraceptive. Obstetrics and Gynecology
36(4). 589-596 . October 1970.
156 SIN, H. w ., PENG . J . Y.. and MARZUKI. D. A. A field study of
Depo Provera : its use as a contraceptive method by women in a
rural town In west Malaysia from February 1968 to December
1969. Medical Journal of MalaYSia 27: 299-305. June 1973.
157 SOICHET. S. Depo-Provera (medroxyprogesterone acetate)
as a female contraceptive agent. International Journal 01 Fenility
14(1): 33 -38 January-March 1969.
158. SPELLACY , W . N. A review of carbohydrate mel6boll sm
and the oral contracePtives. Amencan Journal of Obstetrics and
Gynecology 104 . 44B-460. 1969.
159 SPELLACY, W . N., McLE.OD, A. G. W ., BUHI , W. C.. and
81RK . S. A. The eHect s of medroxyprogeslerone acetate on carbo
hydrale meTabolism: measurements of gluco se. insulin, and
grOWlh hormone after twelve months' use. Fertility and Sterility
23(4) . 239-244. April 1972 .
160 SPELLACY. W. N.. McLEOD. A G. W. BUHI. W. C.. BIRK.
S A., and McCREARY, S. A . Medro;.r.yprogesterone acetate and
carbohydrate metabolism : measurement of glucose, InSulin, and
growth hormone during 6-months ' time Fertility and Sterility 21 :
457-463. 1970.
161. TENHAEFF, D. Hormonanalytlsche Unter suchungen unter
8ehandlung mit neuartlgen Kontrazepliva . (Hormone analytiC
studies during therapy with new contraceptive agents.)Geburt
s'hille und Frauenheilkunde 31: 760-767 . August 1971.

GWU-SCD-75-05P

K-16

163. TIETZE. C.. GUTIMACHER. A. F.. and RUBIN . S. Time re
quired for conceplion of 1727 planned pregnancies . Fertility and
Sterility 1: 338-346 , 1950.

132 RAHMAN , S. A PrOVision of injection Oepo-provera 50
mgm / cc in Malaysia ' s National Family Planning Program 3 p.
(Unpublished)

107. MEY. R. Zur 6a-methyl-17a-acetoxyprogesteron- Th€raple
wahrend der Graviditat.[On 6a-methyl-17a-acetoxyprogesterone
therapy during pregnancy] Geburtshelfe und Frauenheilkunde
23 : 291-300. 1962

109. MISHELL. D .. Jr. Progress repOrt : DMPA for contraception .
Contemporary Ob/ Gyn 3(4): 15-17. April 1974

162. TIETZE. C. Fertility after discontinuation of IOtrauterine and
oral contreception . Internallonal Journal of Fertility 13(4): 385
389. October· December 1968,

(SIDA). Personal communication. October 9,

166. TYLEA, E. T. A contraceptive Injection study emplOYing
medroxyprogeslerone acelale suspension. In ' Selected papers on
anti-fertility agents. repnnted from Proceedings of the Sixth World
Congress on Fertilityand Sterility. Tel Aviv, 1968. Jerusalem. Israel
Academyol Sciences and Humanities, 1970 p. 1· 6
, 67 . TYLER, E. T., LEVIN. M . ELLIOT. J .• and DOLMAN, H. Present
status of injectable contraceptives . results of seven years Study
Fertility and Ste"llty 21 (6) 469 · 481 . June 1970.
168. THE UPJOHN COMPANY . DeDo-Provera. 1974 8 p. (Un.
published)
169. VALLANCE , D . K. and CAPEL-EDWARDS, K. Chlormadinone
and mammary nOdules. [Leiter to the Editor 1 Brilish Medical
Journal 24. 221 ·222 April 24. 1971.
170 Van GINNEKIN, J . K Prolonged breast feeding as a birth
spa Cing meThod. Studies In Family Planning 5(6)' 201·205. June
1974.
171 . VECCHIO, T. J. Injectable me(lroxyprogesteroneacetate con
traception : metaboliC and endocrine effects. Journal of Reproduc 
live Medicine 10(4)' 193-196 April 1973.
172. VECCHIO , T. J . (The Upjohn Company). Personal communi·
cation to G. van der Vlugt. September 18. 1973
173. VECCHIO . T J . (The UpJohn Company) Personal communi 
cation to R.T. Ravenholt. November 9.1967.
174. VECCHIO. T. J. Aeturn of fertility following di scontinuance.
Depo-Provera Research Newsletter NO. 3, January 1972. 4 p.
175. VECCHIO. T. J. "Those wretched beagles." Depo · Provera
Resea rch Newsletter No.7. OCtOber 1973.6 p.
176. WAJNTRAUB. G. Fertility alter removal of the In(rautehne
ring. Fertility and Sterility 21(7): 555 ·564. July 1970.
177. WEL TV, T. K .. JOSIMOV1CH. J B.. GERENDE, J. H.. and
H1NGSON. R. A . Aeductlon of variability in the anovulatory period
following medroxyprogesterone acetate IOJectlon by using jet
inJectors. Fenility and 5te(llity 21 (9): 673-682 September 1970.
178. WILKINS. L. Masculinization of female fetus due to use of
orally given progestins. Journal of the American Medical Associa
tion 172( 10): 1028-1032 . March 5, 1960
179. WILKINS. L .. JONES. H. W .. HOLMAN. G. H.. and STEMP
FEL , R. S. Masculinization of the lema Ie fetus associated wilh
administration of oral and Intramuscular progestins dunng gesta 
tion' non · adrenal female pseudohermaDhrodlsm . Journal of Clini 
cal Endocrinology and Metabolism 18(6): 559 · 585 June 1958.
180. WRIGHT, N H
1974.

Personal communication, September t 3.

181. ZANARTU, J. Ellect of natural and synthetic sex steroids 10
cervical mucus penetration and ascent of spermatozoa . [Abstract]
In ' Proceedings of the Fifth World Congress on Fertility and Slefll
Ily, Stockholm, June 16-22, 1966. Amsterdam, Excerpta Medica,
1967 (International Congress Series No. 133) p 704 .
182. ZANARTU, J . Long-term contraceptive effect of in je ctable
progestogens: inhlbillon and reestablishment of fertility. Interna·
tional Journal of Fertility 13(4): 4' 5·426. OctOber-December
196B
183. ZANARTU. J . A new approach to fertility control. long-acting
Injectable progestogens Advances In Fertility Control 3(3): 41 -43
196B.
184 . ZANARTU, J. and NAVARRO. C. Fertility inhib ition by an
injeCtable progestogen aCling for three months- a clin ical survey
of 130 fertile women trealed with norethisterone enamhate.
Obstetrics and Gynecology 31 (5) : 1627-1633. May 1968
185. ZANARTU, J . and NAVARRO, C. Long·acling proges! agens In
fertility control. In: Proceedings of the SiKlh Pan-American Con 
gressol Endocrinology. MeXICO City. October 10-15, 1965. Am ster 
dam. Excerpta Medica, 1966 (International Congress Serl e&: No.
112)p 134 - 137
186. ZANARTU. J and ONETIO, E. Long ·acting injectable proges·
togens in human fertility control. In: Clinical proceedings of Inter·
national Planned Parenthood Federation SOuth·East Asia & Ocea
nia Regional Medi cal & Scientific Congres s. Sydney. August
14 - 18. 1972. [Sydney JAustralian and New Zealand Journal of
Ob Stetrics and Gynaecology [1972] p 65-79 .
lB7 . ZANARTU. J .. ONETIO . E.. MEDINA. E . andDABANCENS.A.
Mammary gland nodules in women under continuous expoSure to
progestagens. Contraception 7(3) ' 203-212 . March 1973 .
1BB. ZANARTU. J . PUPKIN . M .. ROSENBERG. 0 .. DABAN CENS.
A .. GUERRERO. R. . RODRIGUEZ-BRAVO. R.. and GARC1A
HUIDOBRO. M . Long-Ierm effect of medro;.r.yprogesteron e acetate
In human ovarian morphophysiology and sperm transport . Fertility
and Sterility 21(7 ): 525-533 July 1970
189. ZARTMAN. E A. A long-acting progestational agent as a
contracepti ve method . In . Advances 10 planned parenthood. Pro
ceedings of Ihe Ihlfd and fourth annual meetings of the American
A ssociation of Planned Parenthood Physicians , Chicago. May
1965/ 0enver. April 1966. Am sterdam. Excerpta Medica. 1967.
(International Congress Series No. 13B) p. 116-119.
190. ZARTMAN. E. R. Long-acting Injectable contracept ion w ith
medroxyprogesterone acetate In: Selected papers on anTI -fer tility
agents, reprinted from Proceedings of the Sixth World Congress on
Fertility and Sterility. Tel AVIV. 1968. Jerusalem, Israel Academy of
Sciences and Humanilles, 1970 p. 33-40 .
191. ZATUCHNI , G. I. Family planning via the postpartum ap 
proach . War on Hunger 3(10) 12-'6 October 1969
192 ZATUCHNI, G. l. The post-parium program : a new approach
In. Berelson. B., ed. Family planning programs. an international
SUfVey. New York, 8asic Book, 1969. p. 157-168.

